

FILE 'REGISTRY' ENTERED AT 09:07:15 ON 16 JUN 2008

L1           STRUCTURE UPLOADED

L2           50 S L1

L3       76450 S L1 SSS FULL

L4           STRUCTURE UPLOADED

L5           STRUCTURE UPLOADED

L6           STRUCTURE UPLOADED

L7       42345 S L4   SUB=L3 FULL

L8       9767 S L5   SUB=L7 FULL

L9       3925 S L6   SUB=L8 FULL

FILE 'CAPLUS' ENTERED AT 09:17:01 ON 16 JUN 2008

L10       1698 S L9

FILE 'STNGUIDE' ENTERED AT 09:17:10 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:18:05 ON 16 JUN 2008

L11       122010 S MONOSACCH? OR (BUILDING BLOCK) OR (LIBRARY)

L12       196 S L10 AND L11

L13       160 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'REGISTRY' ENTERED AT 09:22:10 ON 16 JUN 2008

L14       STRUCTURE UPLOADED

L15       337 S L14   SUB=L9 FULL

L16       3588 S L9 NOT L15

FILE 'HCAPLUS' ENTERED AT 09:23:09 ON 16 JUN 2008

L17       1520 S L16

L18       142 S L17 AND L13

FILE 'REGISTRY' ENTERED AT 09:25:30 ON 16 JUN 2008

L19       STRUCTURE UPLOADED

L20       726968 S L19 SSS FULL

L21       1328 S L19   SUB=L16 FULL

L22       2260 S L16 NOT L21

FILE 'HCAPLUS' ENTERED AT 09:27:22 ON 16 JUN 2008

L23       752 S L21

L24       96 S L18 AND L21

FILE 'REGISTRY' ENTERED AT 09:30:37 ON 16 JUN 2008

L25       STRUCTURE UPLOADED

L26       50 S L25

L27       7 S L26   SUB=L2 FULL

L28       0 S L22 NOT L7

L29       2260 S L22 NOT L27

FILE 'HCAPLUS' ENTERED AT 09:34:05 ON 16 JUN 2008

L30       872 S L29

L31       19 S L24 AND L29

=> file registry		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:07:15 ON 16 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0  
DICTIONARY FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Documents and Settings\eolson\My Documents\e-Red  
Folder\10524048\hexosegeneric.str

L1 STRUCTURE UPLOADED

=> d l1  
L1 HAS NO ANSWERS  
L1 STR



G1 O,S  
G2 C,S  
G3 O,S,N  
G4 C,O,S,N  
G5 OH,[@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:07:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 14980 TO ITERATE

13.4% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 292268 TO 306932

PROJECTED ANSWERS: 72399 TO 79797

L2 50 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 09:07:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 303311 TO ITERATE

100.0% PROCESSED 303311 ITERATIONS

76450 ANSWERS

SEARCH TIME: 00.00.05

L3 76450 SEA SSS FUL L1

=> log hold

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST 178.36 178.57

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 09:07:56 ON 16 JUN 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'REGISTRY' AT 09:15:08 ON 16 JUN 2008  
FILE 'REGISTRY' ENTERED AT 09:15:08 ON 16 JUN 2008  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	178.57

=>

=>

Uploading C:\Documents and Settings\eolson\My Documents\e-Red  
Folder\10524048\10524048alkoxy.str

L4 STRUCTURE UPLOADED

=>

Uploading C:\Documents and Settings\eolson\My Documents\e-Red  
Folder\10524048\10524048amino.str

L5 STRUCTURE UPLOADED

=>

Uploading C:\Documents and Settings\eolson\My Documents\e-Red  
Folder\10524048\10524048hydroxy.str

L6 STRUCTURE UPLOADED

=> s 14 sub=13

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full  
FULL SUBSET SEARCH INITIATED 09:16:22 FILE 'REGISTRY'  
FULL SUBSET SCREEN SEARCH COMPLETED - 74996 TO ITERATE

100.0% PROCESSED 74996 ITERATIONS 42345 ANSWERS  
SEARCH TIME: 00.00.01

L7 42345 SEA SUB=L3 SSS FUL L4

=> s 15 sub=17

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full  
FULL SUBSET SEARCH INITIATED 09:16:39 FILE 'REGISTRY'  
FULL SUBSET SCREEN SEARCH COMPLETED - 10196 TO ITERATE

100.0% PROCESSED 10196 ITERATIONS 9767 ANSWERS  
SEARCH TIME: 00.00.01

L8 9767 SEA SUB=L7 SSS FUL L5

=> s 16 sub=18

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 09:16:53 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 9767 TO ITERATE

100.0% PROCESSED 9767 ITERATIONS

3925 ANSWERS

SEARCH TIME: 00.00.01

L9 3925 SEA SUB=L8 SSS FUL L6

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

306.04

306.25

FILE 'CAPLUS' ENTERED AT 09:17:01 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25

FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 19

L10 1698 L9

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.48

306.73

FILE 'STNGUIDE' ENTERED AT 09:17:10 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jun 13, 2008 (20080613/UP).

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.12

306.85

FILE 'HCAPLUS' ENTERED AT 09:18:05 ON 16 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25  
FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s monosacch? or (building block) or (library)

```
      25485 MONOSACCH?
      133674 BUILDING
      269519 BLOCK
      8086 BUILDING BLOCK
          (BUILDING(W)BLOCK)
      88814 LIBRARY
L11      122010 MONOSACCH? OR (BUILDING BLOCK) OR (LIBRARY)
```

=> s l10 and l11

```
      1698 L9
L12      196 L10 AND L11
```

=> s l12 and (PY<2003 or AY<2003 or PRY<2003)

```
      22930220 PY<2003
      4482946 AY<2003
      3958496 PRY<2003
L13      160 L12 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.69	309.54

FILE 'STNGUIDE' ENTERED AT 09:18:11 ON 16 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jun 13, 2008 (20080613/UP).

<-----User Break----->

=> d 113 1-20 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

- L13 ANSWER 1 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Preparation of oligosaccharide uronates, corresponding to fragments of natural mucopolysaccharides, and their biological applications
- L13 ANSWER 2 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
- L13 ANSWER 3 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Tetrahydropyran compounds that interact with G protein-coupled receptors (GPCRs)
- L13 ANSWER 4 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
- L13 ANSWER 5 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Synthesis of monosulfated saccharides in the spacered form
- L13 ANSWER 6 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI D-Glucose as a multivalent chiral scaffold for combinatorial chemistry
- L13 ANSWER 7 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Synthesis of tools for raising antibodies against moenomycin epitopes and initial immunological studies
- L13 ANSWER 8 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Combinatorial libraries of glucosamine monosaccharides
- L13 ANSWER 9 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI "Meshed-Bag Gathered-Bunch" Method for Solid-Phase Synthesis of Small Molecular Diverse Compounds
- L13 ANSWER 10 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI New efficient route for synthesis of lipid A by using affinity separation
- L13 ANSWER 11 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Linear Synthesis of a Protected H-Type II Pentasaccharide Using Glycosyl Phosphate Building Blocks
- L13 ANSWER 12 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Synthesis of a building block for phosphonate analogs of moenomycin A12 from D-tartaric acid
- L13 ANSWER 13 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Study of glycosylation with N-trichloroacetyl-D-glucosamine derivatives in the syntheses of the spacer-armed pentasaccharides sialyl lacto-N-neotetraose and sialyl lacto-N-tetraose, their fragments, and analogues
- L13 ANSWER 14 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Synthesis of the Fully Phosphorylated GPI Anchor Pseudohexasaccharide of Toxoplasma gondii
- L13 ANSWER 15 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI DISAL glycosyl donors for efficient glycosylations under acidic conditions: Application to solid-phase oligosaccharide synthesis

L13 ANSWER 16 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Aptamers that bind to the antibiotic moenomycin A

L13 ANSWER 17 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Substrate Specificity of the Glycosyl Donor for Oligosaccharyl Transferase


L13 ANSWER 18 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Methods for solid phase synthesis of  $\alpha$ -D-Gal-(1,3)-Gal-containing oligosaccharides

L13 ANSWER 19 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Chemoenzymatic-chemical synthesis of a (2-3)-sialyl T threonine building block and its application to the synthesis of the N-terminal sequence of leukemia-associated leukosialin (CD 43)

L13 ANSWER 20 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Preparation of oligosaccharide lipid-A analogs as antitumor and immunostimulating agents

=> d l13 1-10 ti abs bib hitstr  
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L13 ANSWER 1 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Preparation of oligosaccharide uronates, corresponding to fragments of natural mucopolysaccharides, and their biological applications  
 GI



AB The invention relates to a process for the organic synthesis of oligosaccharides constituting or comprising fragments of acid mucopolysaccharides comprising the reaction of two compds. constituted or terminated by units of glucosamine structure and of uronic acid structure resp., said units being specifically substituted. This process particularly enables valuable anticoagulant drugs to be obtained. Mucopolysaccharide fragments were synthesized. Thus the pentasaccharide I was prepd from the monosaccharides in a synthesis comprising many steps. I has factor Xa antagonist activity >2000 U/mg.

AN 2008:603607 HCAPLUS <<LOGINID::20080616>>  
 DN 148:517928  
 TI Preparation of oligosaccharide uronates, corresponding to fragments of natural mucopolysaccharides, and their biological applications




IN Petitou, Maurice; Jacquinet, Jean-Claude; Sinay;, Pierre; Choay;, Jean;  
 Lormeau;, Jean-Claude; Nassr;, Mahmoud  
 PA Choay SA, Fr.  
 SO U.S., 84pp., Cont. of U.S. Ser. No. 457,931, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 4818816	A	19890404	US 1987-115593	19871026 <--
	FR 2504535	A1	19821029	FR 1981-8472	19810428 <--
	FR 2504535	B1	19870814		
	FR 2519987	A1	19830722	FR 1982-621	19820115 <--
	FR 2520744	A1	19830805	FR 1982-1575	19820201 <--
	FR 2521566	A1	19830819	FR 1982-2526	19820216 <--
	AU 8283955	A	19821124	AU 1982-83955	19820428 <--
	AU 558472	B2	19870129		
	JP 58500564	T	19830414	JP 1982-501461	19820428 <--
	JP 03013240	B	19910222		
	FR 2527614	A1	19831202	FR 1982-9392	19820528 <--
	FR 2528853	A1	19831223	FR 1982-10891	19820622 <--
	FR 2528854	A1	19831223	FR 1982-10892	19820622 <--
	FR 2529557	A1	19840106	FR 1982-11679	19820702 <--
	FR 2531436	A1	19840210	FR 1982-13804	19820806 <--
	FR 2533219	A1	19840323	FR 1982-15803	19820920 <--
	FR 2533220	A1	19840323	FR 1982-15804	19820920 <--
	FR 2535324	A1	19840504	FR 1982-18003	19821027 <--
	US 4987223	A	19910122	US 1982-453731	19821027 <--
	US 4607025	A	19860819	US 1982-451615	19821220 <--
	SU 1470196	A3	19890330	SU 1982-3528900	19821227 <--
	DK 8205756	A	19821228	DK 1982-5756	19821228 <--
	DK 8300143	A	19830716	DK 1983-143	19830114 <--
	DK 174348	B1	20021223		
	SU 1694065	A3	19911123	SU 1983-3545151	19830114 <--
	AU 8321285	A	19840522	AU 1983-21285	19831027 <--
	AU 581167	B2	19890216		
	JP 59501906	T	19841115	JP 1983-503432	19831027 <--
	JP 05066392	B	19930921		
	AT 40555	T	19890215	AT 1983-402109	19831027 <--
	DK 8403135	A	19840627	DK 1984-3135	19840627 <--
	DK 175970	B1	20051003		
	US 4943630	A	19900724	US 1986-856855	19860421 <--
PRAI	FR 1981-8472	A	19810428	<--	
	FR 1982-621	A	19820115	<--	
	FR 1982-1575	A	19820201	<--	
	FR 1982-2526	A	19820216	<--	
	FR 1982-9392	A	19820528	<--	
	FR 1982-10891	A	19820622	<--	
	FR 1982-10892	A	19820622	<--	
	FR 1982-11679	A	19820702	<--	
	FR 1982-13804	A	19820806	<--	
	FR 1982-15803	A	19820920	<--	
	FR 1982-15804	A	19820920	<--	
	FR 1982-18003	A	19821027	<--	
	US 1982-451615	A2	19821220	<--	
	US 1983-457931	A1	19830114	<--	
	FR 1981-24132	A	19811223	<--	
	WO 1982-FR76	A	19820428	<--	
	FR 1982-18001	A	19821027	<--	
	EP 1983-402109	A	19831027	<--	


WO 1983-FR217                    A            19831027   <--  
 US 1984-624628                  A            19840626   <--  
 OS    MARPAT 148:517928  
 IT    26922-15-6  
       RL: RCT (Reactant); RACT (Reactant or reagent)  
          (preparation of oligosaccharide uronats, corresponding to fragments of  
          natural mucopolysaccharides, and their biol. applications)  
 RN    26922-15-6    HCAPLUS  
 CN     $\alpha$ -D-Glucopyranoside, phenylmethyl 2-deoxy-2-  
       [[(phenylmethoxy)carbonyl]amino]-3-O-(phenylmethyl)-    (CA INDEX NAME)

Absolute stereochemistry.




IT    69892-44-0P 85193-92-6P 87907-06-0P  
       87907-35-5P 87907-36-6P  
       RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
          (Reactant or reagent)  
          (preparation of oligosaccharide uronats, corresponding to fragments of  
          natural mucopolysaccharides, and their biol. applications)  
 RN    69892-44-0    HCAPLUS  
 CN     $\alpha$ -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-3-O-  
       (phenylmethyl)- (9CI)    (CA INDEX NAME)

Absolute stereochemistry.



RN    85193-92-6    HCAPLUS  
 CN     $\alpha$ -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-3,6-bis-O-  
       (phenylmethyl)-    (CA INDEX NAME)


Absolute stereochemistry.



RN 87907-06-0 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, phenylmethyl 2-deoxy-2-  
[[ (phenylmethoxy)carbonyl]amino]-3-O-(phenylmethyl)-, 6-acetate (CA INDEX  
NAME)


Absolute stereochemistry.



RN 87907-35-5 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, methyl 2-deoxy-2-[[ (phenylmethoxy)carbonyl]amin  
o]-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 87907-36-6 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, methyl 2-deoxy-2-[[ (phenylmethoxy)carbonyl]amin  
o]-3-O-(phenylmethyl)-, 6-benzoate (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy  
 AB The present invention provides, inter alia, peptides, peptide dimer, and  
 multimeric complexes comprising at least one binding moiety for KDR or  
 VEGF/KDR complex, which have a variety of uses wherever treating,  
 detecting, isolating or localizing angiogenesis is advantageous.  
 Particularly disclosed are synthetic, isolated polypeptides capable of  
 binding KDR or VEGF/KDR complex with high affinity (e.g., having a  $KD < 1$   
 $\mu M$ ), and dimer and multimeric constructs comprising these polypeptides.  
 AN 2005:1201059 HCAPLUS <<LOGINID::20080616>>  
 DN 143:483093  
 TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy  
 IN Sato, Aaron K.; Sexton, Daniel J.; Dransfield, Daniel T.; Ladner, Robert  
 C.; Arbogast, Christophe; Bussat, Phillipe; Fan, Hong; Khurana, Sudha;  
 Linder, Karen E.; Marinelli, Edmund R.; Nanjappan, Palaniappa; Nunn,  
 Adrian D.; Pillai, Radhakrishna; Pochon, Sibylle; Ramalingam,  
 Kondareddiar; Shrivastava, Ajay; Song, Bo; Swenson, Rolf E.; Von Wronski,  
 Mathew A.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 436 pp., Cont.-in-part of U.S. Ser. No. 661,156.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050250700	A1	20051110	US 2004-939890	20040913 <--
	WO 2003074005	A2	20030912	WO 2003-US6731	20030303 <--
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050100963	A1	20050512	US 2003-661156	20030911 <--
	WO 2006031885	A2	20060323	WO 2005-US32740	20050913
	WO 2006031885	A3	20060817		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				
	LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,				

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
 ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

PRAI US 2002-360851P P 20020301 <--  
 US 2003-440411P P 20030115  
 US 2003-382082 B2 20030303  
 WO 2003-US6731 A2 20030303  
 US 2003-661156 A2 20030911  
 US 2004-939890 A 20040913


IT 599211-70-8P 599211-95-7P  
 RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy)



RN 599211-70-8 HCAPLUS

CN L-Lysinamide, N-acetyl-L-valyl-L-cysteinyl-L-tryptophyl-L- $\alpha$ -glutamyl-L- $\alpha$ -aspartyl-L-seryl-L-tryptophylglycylglycyl-L- $\alpha$ -glutamyl-L-valyl-L-cysteinyl-L-phenylalanyl-L-arginyl-L-tyrosyl-L- $\alpha$ -aspartyl-L-prolylglycylglycylglycyl-N6-[O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\alpha$ -D-galactopyranosyl]-L-serylglycyl-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\alpha$ -D-galactopyranosyl]-L-seryl]-, cyclic (2 $\rightarrow$ 12)-disulfide (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






PAGE 1-D




PAGE 2-A

Ph

PAGE 2-B



PAGE 2-C




RN 599211-95-7 HCAPLUS  
CN L-Lysinamide, N-acetyl-L-valyl-L-cysteinyl-L-tryptophyl-L- $\alpha$ -glutamyl-


L- $\alpha$ -aspartyl-L-seryl-L-tryptophylglycylglycyl-L- $\alpha$ -glutamyl-L-valyl-L-cysteinyl-L-phenylalanyl-L-arginyl-L-tyrosyl-L- $\alpha$ -aspartyl-L-prolylglycylglycylglycyl-N6-[N-[5-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,5-dioxopentyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\alpha$ -D-galactopyranosyl]-L-serylglycyl-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\alpha$ -D-galactopyranosyl]-L-seryl]-, cyclic (2 $\rightarrow$ 12)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 1-C




PAGE 2-A

Ph


PAGE 2-B



PAGE 2-C



L13 ANSWER 3 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Tetrahydropyran compounds that interact with G protein-coupled receptors  
 (GPCRs)  
 GI



AB The invention discloses a method of inhibiting or effecting the activity of a GPCR which comprises contacting a GPCR with a compound I [Z = S, O, NRA (RA = R1-R5, C1-15 acyl, etc.); X = O, NRA; R1-R5 = H, C1-12 alkyl, C4-15 aryl, etc.; with provisos; ring may be of any configuration], or a pharmaceutically acceptable salt thereof. Libraries of compds. of the invention were tested for activity in assays using melanocortin and somatostatin receptors.

AN 2004:333585 HCAPLUS <<LOGINID::20080616>>

DN 140:350624

TI Tetrahydropyran compounds that interact with G protein-coupled receptors (GPCRs)

IN Meutermans, Wim; Thanh, Giang Le; Abbenante, Giovanni; Tometzki, Gerald; Halliday, Judy; Zeugg, Johannes

PA Alchemia Pty. Ltd., Australia

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004032940	A1	20040422	WO 2003-AU1347	20031010 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499677	A1	20040422	CA 2003-2499677	20031010 <--
	AU 2003266858	A1	20040504	AU 2003-266858	20031010 <--
	AU 2003266858	B2	20060914		
	EP 1549325	A1	20050706	EP 2003-747740	20031010 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1703228	A	20051130	CN 2003-80101113	20031010 <--
	JP 2006504718	T	20060209	JP 2004-542106	20031010 <--
	US 20060223764	A1	20061005	US 2003-530851	20031010 <--
	IN 2005KN00858	A	20060609	IN 2005-KN858	20050511 <--
	IN 2007KN03028	A	20071130	IN 2007-KN3028	20070817 <--


PRAI AU 2002-951995 A 20021011 <--  
 WO 2003-AU1347 W 20031010  
 IN 2005-KN858 A3 20050511  
 OS MARPAT 140:350624  
 IT 681150-90-3  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (202tetrahydropyran compds. that interact with G protein-coupled  
 receptors)  
 RN 681150-90-3 HCAPLUS  
 CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-  
 deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 681172-12-3 681172-78-1 681173-27-3  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (ktetrahydropyran compds. that interact with G protein-coupled  
 receptors)  
 RN 681172-12-3 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-  
 3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio-  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 681172-78-1 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-  
 2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-27-3 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



IT 681147-35-3 681147-36-4 681147-37-5  
681147-38-6 681147-39-7 681147-40-0  
681147-41-1 681147-42-2 681147-43-3  
681147-44-4 681147-45-5 681147-46-6  
681147-47-7 681147-48-8 681147-49-9  
681147-50-2 681147-51-3 681147-52-4  
681147-53-5 681147-54-6 681147-55-7  
681147-56-8 681147-57-9 681147-58-0  
681147-59-1 681147-60-4 681147-61-5  
681147-62-6 681147-63-7 681147-64-8  
681147-65-9 681147-66-0 681147-68-2  
681147-69-3 681147-70-6 681147-71-7  
681147-72-8 681147-73-9 681147-74-0  
681147-75-1 681147-76-2 681147-77-3  
681147-78-4 681147-79-5 681147-80-8  
681147-81-9 681147-82-0 681147-83-1  
681147-84-2 681147-85-3 681147-86-4  
681147-87-5 681147-88-6 681147-89-7  
681147-90-0 681147-91-1 681147-92-2  
681147-93-3 681147-94-4 681147-95-5  
681147-96-6 681147-97-7 681147-98-8

681147-99-9 681148-00-5 681148-01-6  
681148-02-7 681148-03-8 681148-04-9  
681148-05-0 681148-06-1 681148-07-2  
681148-08-3 681148-09-4 681148-10-7  
681148-11-8 681148-12-9 681148-13-0  
681148-14-1 681148-15-2 681148-16-3  
681148-17-4 681148-18-5 681148-19-6  
681148-20-9 681148-21-0 681148-22-1  
681148-23-2 681148-24-3 681148-25-4  
681148-26-5 681148-27-6 681148-28-7  
681148-29-8 681148-30-1 681148-31-2  
681148-32-3 681148-33-4 681148-34-5  
681148-35-6 681148-36-7 681148-37-8  
681148-38-9 681148-39-0 681148-40-3  
681148-41-4 681148-42-5 681148-43-6  
681148-44-7 681148-45-8 681148-46-9  
681148-47-0 681148-48-1 681148-49-2  
681148-50-5 681148-51-6 681150-14-1  
681150-16-3 681150-20-9 681150-22-1  
681150-25-4 681150-27-6 681150-28-7  
681150-31-2 681150-32-3 681150-33-4  
681150-34-5 681150-39-0 681150-40-3  
681150-41-4 681150-42-5 681150-43-6  
681150-44-7 681150-45-8 681150-46-9  
681150-47-0 681150-48-1 681150-49-2  
681150-50-5 681150-51-6 681150-52-7  
681150-53-8 681150-54-9 681150-55-0  
681150-56-1 681150-57-2 681150-58-3  
681150-59-4 681150-60-7 681150-61-8  
681150-62-9 681150-63-0 681150-64-1  
681150-65-2 681150-66-3 681150-67-4  
681150-68-5 681150-69-6 681150-70-9  
681150-71-0 681150-72-1 681150-73-2  
681150-74-3 681150-75-4 681150-76-5  
681150-77-6 681150-78-7 681150-79-8  
681150-80-1 681150-81-2 681150-82-3  
681150-83-4 681150-84-5 681150-85-6  
681150-86-7 681150-87-8 681150-88-9  
681150-89-0 681150-91-4 681150-92-5  
681150-93-6 681150-94-7 681150-95-8  
681150-96-9 681150-97-0 681150-98-1  
681150-99-2 681151-00-8 681151-01-9  
681151-02-0 681151-03-1 681151-04-2  
681151-05-3 681151-06-4 681151-07-5  
681151-08-6 681151-09-7 681151-10-0  
681151-11-1 681151-12-2 681151-13-3  
681151-14-4 681151-15-5 681151-16-6  
681151-17-7 681151-18-8 681151-19-9  
681151-20-2 681151-21-3 681151-22-4  
681151-23-5 681151-24-6 681151-25-7  
681151-26-8 681151-27-9 681151-28-0  
681151-29-1 681151-31-5 681151-32-6  
681151-33-7 681151-34-8 681151-35-9  
681151-36-0 681151-37-1 681151-38-2  
681151-39-3 681151-40-6 681151-41-7  
681151-42-8 681151-43-9 681151-44-0  
681151-45-1 681151-46-2 681151-47-3  
681151-48-4 681151-49-5


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(tetrahydropyran compds. that interact with G protein-coupled

receptors)

RN 681147-35-3 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-  
2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-36-4 HCAPLUS


CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-  
naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-37-5 HCAPLUS  
 CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-38-6 HCAPLUS  
 CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681147-39-7 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-40-0 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-41-1 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.






RN 681147-42-2 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-43-3 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681147-44-4 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-45-5 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-46-6 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-47-7 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-48-8 HCAPLUS


CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-49-9 HCAPLUS  
 CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-50-2 HCAPLUS  
 CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681147-51-3 HCAPLUS  
 CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-52-4 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-53-5 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[[4-[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-54-6 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-55-7 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-56-8 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-57-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-58-0 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-59-1 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.






RN 681147-60-4 HCAPLUS  
 CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-61-5 HCAPLUS  
 CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 681147-62-6 HCAPLUS  
 CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-63-7 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-  
[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-  
ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-64-8 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-  
[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-  
naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-65-9 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-  
(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-66-0 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-  
2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-68-2 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-69-3 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-70-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-71-7 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-72-8 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-73-9 HCAPLUS


CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-74-0 HCAPLUS  
 CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-75-1 HCAPLUS  
 CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681147-76-2 HCAPLUS  
 CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-77-3 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-78-4 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 681147-79-5 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-80-8 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-81-9 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-82-0 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-83-1 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-84-2 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-85-3 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-86-4 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-87-5 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-88-6 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-89-7 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-90-0 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-  
2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-91-1 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-  
ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-92-2 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-  
[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-  
ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-93-3 HCAPLUS


CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-  
naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681147-94-4 HCAPLUS  
 CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
 [(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-methyl-6-O-(2-  
 naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-95-5 HCAPLUS  
 CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-  
 oxobutyl)amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX  
 NAME)


Absolute stereochemistry.






RN 681147-96-6 HCAPLUS  
 CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-  
 [(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-methyl-6-O-(2-  
 naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-97-7 HCAPLUS  
 CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
 [[[aminoiminomethyl]amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-  
 deoxy-3-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-98-8 HCAPLUS  
 CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
 [(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-  
 2-deoxy-3-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 681147-99-9 HCAPLUS  
 CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-  
 oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 681148-00-5 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-  
[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-  
deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-01-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acety  
l]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 681148-02-7 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-03-8 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-04-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-05-0 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-06-1 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-07-2 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-08-3 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-09-4 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-10-7 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681148-11-8 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 681148-12-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-13-0 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-14-1 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-15-2 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-16-3 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-17-4 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-18-5 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-19-6 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-20-9 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-21-0 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-22-1 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-23-2 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-24-3 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-25-4 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-methyl-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-26-5 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-27-6 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681148-28-7 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 681148-29-8 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-30-1 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-31-2 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-32-3 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-33-4 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-34-5 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-35-6 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-36-7 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-37-8 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-38-9 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-39-0 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-40-3 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-41-4 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-42-5 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-[(3-hydroxyphenyl)methyl]-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-43-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-[(3-hydroxyphenyl)methyl]-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-44-7 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-[(3-hydroxyphenyl)methyl]-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-45-8 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-[(3-hydroxyphenyl)methyl]-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-46-9 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-47-0 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681148-48-1 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 681148-49-2 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-50-5 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-51-6 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-14-1 HCAPLUS

CN D-Glucopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1-oxo-3-phenylpropyl)amino]-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-16-3 HCAPLUS

CN D-Glucopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1H-indol-3-ylacetyl)amino]-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-20-9 HCAPLUS

CN D-Glucopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-22-1 HCAPLUS

CN D-Glucopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-6-O-[(4-


chlorophenyl)methyl]-2-deoxy-2-[(1H-indol-3-ylacetyl)amino]-1-thio- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 681150-25-4 HCAPLUS  
CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-  
[(phenylacetyl)amino]-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681150-27-6 HCAPLUS  
CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1H-indol-  
3-ylacetyl)amino]-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-28-7 HCAPLUS  
CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[[3-(1H-

indol-3-yl)-1-oxopropyl]amino]-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-31-2 HCAPLUS

CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1-oxo-3-phenyl-2-propen-1-yl)amino]-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 681150-32-3 HCAPLUS

CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-33-4 HCAPLUS

CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-2-[(1-oxo-3-phenyl-2-propen-1-yl)amino]-1-thio- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 681150-34-5 HCAPLUS

CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-2-[(1H-indol-3-ylacetyl)amino]-1-thio- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 681150-39-0 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-40-3 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-41-4 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-42-5 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-43-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 681150-44-7 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-45-8 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-46-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-47-0 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-48-1 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-49-2 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-50-5 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-51-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-52-7 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-53-8 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-54-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-55-0 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-56-1 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-57-2 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-58-3 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-59-4 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 681150-60-7 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-61-8 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-62-9 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-63-0 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-64-1 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-65-2 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-66-3 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-67-4 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-68-5 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-69-6 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-70-9 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-71-0 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-72-1 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-73-2 HCAPLUS


CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-74-3 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681150-75-4 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-76-5 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 681150-77-6 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-78-7 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-79-8 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-

chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-80-1 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-81-2 HCAPLUS


CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-82-3 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-83-4 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681150-84-5 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-85-6 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-86-7 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-87-8 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-  
[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-88-9 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3,6-  
bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-89-0 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-  
deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-91-4 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-92-5 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-93-6 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-94-7 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-95-8 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-96-9 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 681150-97-0 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-98-1 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-99-2 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-00-8 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-01-9 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-02-0 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-03-1 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-04-2 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-05-3 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-06-4 HCAPLUS


CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681151-07-5 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-  
 2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681151-08-6 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-  
 2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 681151-09-7 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-  
 6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-10-0 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-11-1 HCAPLUS


CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681151-12-2 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681151-13-3 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-14-4 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 681151-15-5 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-16-6 HCAPLUS


CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681151-17-7 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681151-18-8 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681151-19-9 HCAPLUS  
 CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-20-2 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-21-3 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-phenylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-22-4 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
 [[[aminoiminomethyl]amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-  
 deoxy-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-23-5 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
 [[[aminoiminomethyl]amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-  
 deoxy-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-24-6 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
[[[(aminoiminomethyl)amino]acetyl]amino]-3,6-bis-O-[(4-  
chlorophenyl)methyl]-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-25-7 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-(2-  
naphthalenylmethyl)-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-26-8 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-  
deoxy-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-27-9 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-  
2-deoxy-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-28-0 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-  
 [[[ (aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-  
 6-O-[(4-chlorophenyl)methyl]-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-29-1 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
 [(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-  
 2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-31-5 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-  
2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681151-32-6 HCAPLUS



CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3,6-bis-O-[(4-  
chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-33-7 HCAPLUS


CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3,6-bis-O-(2-  
naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681151-34-8 HCAPLUS  
 CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
 [(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-(2-  
 naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681151-35-9 HCAPLUS  
 CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
 [(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-  
 2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-36-0 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-  
ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-37-1 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-  
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-  
ylmethyl)-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-38-2 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-39-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-40-6 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 681151-41-7 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-42-8 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-43-9 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 681151-44-0 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-45-1 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-46-2 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681151-47-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 681151-48-4 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-49-5 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-  
(CA INDEX NAME)

Absolute stereochemistry.



IT	681151-50-8	681151-51-9	681151-52-0
	681151-53-1	681151-54-2	681151-55-3
	681151-56-4	681171-65-3	681171-66-4
	681171-67-5	681171-68-6	681171-69-7
	681171-70-0	681171-71-1	681171-72-2
	681171-73-3	681171-74-4	681171-75-5
	681171-76-6	681171-77-7	681171-78-8
	681171-79-9	681171-80-2	681171-81-3
	681171-82-4	681171-83-5	681171-84-6
	681171-85-7	681171-86-8	681171-87-9
	681171-88-0	681171-89-1	681171-90-4
	681171-91-5	681171-92-6	681171-93-7
	681171-94-8	681171-95-9	681171-96-0
	681171-97-1	681171-98-2	681171-99-3
	681172-00-9	681172-01-0	681172-02-1
	681172-03-2	681172-04-3	681172-05-4
	681172-06-5	681172-07-6	681172-08-7
	681172-09-8	681172-10-1	681172-11-2
	681172-13-4	681172-14-5	681172-15-6
	681172-16-7	681172-17-8	681172-18-9
	681172-19-0	681172-20-3	681172-21-4
	681172-22-5	681172-23-6	681172-24-7
	681172-25-8	681172-26-9	681172-27-0
	681172-28-1	681172-29-2	681172-30-5
	681172-31-6	681172-32-7	681172-33-8
	681172-34-9	681172-35-0	681172-36-1
	681172-37-2	681172-38-3	681172-39-4
	681172-40-7	681172-41-8	681172-42-9
	681172-43-0	681172-44-1	681172-45-2
	681172-46-3	681172-47-4	681172-48-5


681172-49-6 681172-50-9 681172-51-0  
681172-52-1 681172-53-2 681172-54-3  
681172-55-4 681172-56-5 681172-57-6  
681172-58-7 681172-59-8 681172-60-1  
681172-61-2 681172-62-3 681172-63-4  
681172-64-5 681172-65-6 681172-66-7  
681172-67-8 681172-68-9 681172-69-0  
681172-70-3 681172-71-4 681172-72-5  
681172-73-6 681172-74-7 681172-75-8  
681172-76-9 681172-77-0 681172-79-2  
681172-80-5 681172-81-6 681172-82-7  
681172-83-8 681172-84-9 681172-85-0  
681172-86-1 681172-88-3 681172-89-4  
681172-90-7 681172-91-8 681172-92-9  
681172-93-0 681172-94-1 681172-95-2  
681172-96-3 681172-97-4 681172-98-5  
681172-99-6 681173-00-2 681173-01-3  
681173-02-4 681173-03-5 681173-04-6  
681173-05-7 681173-06-8 681173-07-9  
681173-08-0 681173-09-1 681173-10-4  
681173-11-5 681173-12-6 681173-13-7  
681173-14-8 681173-15-9 681173-16-0  
681173-17-1 681173-18-2 681173-19-3  
681173-20-6 681173-21-7 681173-22-8  
681173-23-9 681173-24-0 681173-25-1  
681173-26-2 681173-28-4 681173-29-5  
681173-30-8 681173-31-9 681173-32-0  
681173-33-1 681173-34-2 681173-35-3  
681173-36-4 681173-37-5 681173-38-6  
681173-39-7 681173-40-0 681173-41-1  
681173-42-2 681173-43-3 681173-44-4  
681173-45-5 681173-46-6 681173-47-7  
681173-48-8 681173-49-9 681173-50-2  
681173-51-3 681173-52-4 681173-53-5  
681173-54-6 681173-55-7 681173-56-8  
681173-57-9 681173-58-0 681173-59-1  
681173-60-4 681173-61-5 681173-62-6  
681173-64-8 681173-66-0 681173-70-6  
681173-73-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(tetrahydropyran compds. that interact with G protein-coupled  
receptors)

RN 681151-50-8 HCAPLUS


CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 681151-51-9 HCAPLUS  
 CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681151-52-0 HCAPLUS  
 CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-53-1 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-54-2 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-55-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-56-4 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-65-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-66-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-67-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-68-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681171-69-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.






RN 681171-70-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-71-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-72-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-73-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-74-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-75-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-76-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-77-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-78-8 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-79-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-80-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-81-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-82-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-83-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-84-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-85-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-86-8 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-87-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-88-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-89-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-90-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-91-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-92-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.






RN 681171-93-7 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681171-94-8 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.



RN 681171-95-9 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-96-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-97-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-98-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-99-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-00-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-01-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-6-O-([1,1'-biphenyl]-4-

ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-02-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-03-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-04-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-05-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-06-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-07-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-08-7 HCAPLUS


CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-09-8 HCAPLUS  
CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-10-1 HCAPLUS  
CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.



RN 681172-11-2 HCAPLUS  
CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-13-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-14-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 681172-15-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-16-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-17-8 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-18-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-19-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-20-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-21-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-22-5 HCAPLUS


CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-23-6 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)

Absolute stereochemistry.



RN 681172-24-7 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-25-8 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3,6-bis-O-([1,1'-biphenyl]-

4-ylmethyl)-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-26-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3,6-bis-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-27-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3,6-bis-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-28-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3,6-bis-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-29-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3,6-bis-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-30-5 HCAPLUS


CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3,6-bis-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-31-6 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-32-7 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681172-33-8 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-34-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-35-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.






RN 681172-36-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-37-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-38-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-39-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-40-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-41-8 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-42-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-43-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-44-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 681172-45-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-46-3 HCAPLUS


CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-47-4 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-48-5 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.



RN 681172-49-6 HCAPLUS  
 CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-50-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-51-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-52-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-

naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-53-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-54-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-55-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-56-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-57-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.






RN 681172-58-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-59-8 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-60-1 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-

2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-61-2 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-62-3 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-63-4 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-64-5 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-65-6 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-66-7 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-67-8 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-68-9 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-69-0 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-70-3 HCAPLUS


CN D-Allopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-71-4 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-72-5 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681172-73-6 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-74-7 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-75-8 HCAPLUS


CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-76-9 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 681172-77-0 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-79-2 HCAPLUS  
 CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 681172-80-5 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-81-6 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-82-7 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-83-8 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-84-9 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-85-0 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-86-1 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-88-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-89-4 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-90-7 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-91-8 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-92-9 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-93-0 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-94-1 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA

INDEX NAME)


Absolute stereochemistry.



RN 681172-95-2 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-96-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-97-4 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.






RN 681172-98-5 HCAPLUS  
 CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-99-6 HCAPLUS  
 CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-00-2 HCAPLUS  
 CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-01-3 HCAPLUS  
 CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681173-02-4 HCAPLUS  
 CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-03-5 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-04-6 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-05-7 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-06-8 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-07-9 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-08-0 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-09-1 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-10-4 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-11-5 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-12-6 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-13-7 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-14-8 HCAPLUS


CN D-Allopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-15-9 HCAPLUS  
CN D-Allopyranoside, 2-phenylethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 681173-16-0 HCAPLUS  
CN D-Allopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-17-1 HCAPLUS  
CN D-Allopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 681173-18-2 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-19-3 HCAPLUS


CN D-Allopyranoside, 2-phenylethyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-20-6 HCAPLUS  
 CN D-Allopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-21-7 HCAPLUS  
 CN D-Allopyranoside, 2-phenylethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 681173-22-8 HCAPLUS  
 CN D-Allopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-23-9 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-24-0 HCAPLUS


CN D-Allopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-25-1 HCAPLUS  
 CN D-Allopyranoside, 2-phenylethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-26-2 HCAPLUS  
 CN D-Allopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681173-28-4 HCAPLUS  
 CN D-Allopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-29-5 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-30-8 HCAPLUS


CN D-Allopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-31-9 HCAPLUS  
 CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-32-0 HCAPLUS  
 CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681173-33-1 HCAPLUS  
 CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-34-2 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-35-3 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-36-4 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-37-5 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-38-6 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 681173-39-7 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-40-0 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-41-1 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-  
[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-42-2 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-  
oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 681173-43-3 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(aminooacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-44-4 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-45-5 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-46-6 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-47-7 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-48-8 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-49-9 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-50-2 HCAPLUS


CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-51-3 HCAPLUS  
 CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-52-4 HCAPLUS  
 CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-53-5 HCAPLUS  
 CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-54-6 HCAPLUS  
 CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681173-55-7 HCAPLUS  
 CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-1-thio-, 6-benzeneacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-56-8 HCAPLUS  
 CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-1-thio-, 6-(1H-indole-3-carboxylate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 681173-57-9 HCAPLUS  
 CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-  
 [(phenylacetyl)amino]-1-thio-, 6-(1H-indole-3-acetate) (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 681173-58-0 HCAPLUS  
 CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-  
 [(phenylacetyl)amino]-1-thio-, 6-(1H-indole-3-propanoate) (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



RN 681173-59-1 HCAPLUS

CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-[[ (4-chlorophenyl)acetyl]amino]-2-deoxy-1-thio-, 6-benzoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-60-4 HCAPLUS

CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-[[ (4-chlorophenyl)acetyl]amino]-2-deoxy-1-thio-, 6-benzeneacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-61-5 HCAPLUS


CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-[[ (4-chlorophenyl)acetyl]amino]-2-deoxy-1-thio-, 6-(1H-indole-3-carboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-62-6 HCAPLUS  
 CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-[[ (4-chlorophenyl)acetyl]amino]-2-deoxy-1-thio-, 6-(1H-indole-3-acetate) (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-64-8 HCAPLUS  
 CN D-Allopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-66-0 HCAPLUS  
 CN D-Allopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1H-indol-3-ylacetyl)amino]-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681173-70-6 HCAPLUS  
 CN D-Allopyranoside, (4-chlorophenyl)methyl 2-deoxy-2-[(2,3-diamino-1-oxopropyl)amino]-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681173-73-9 HCAPLUS  
 CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy  
 AB The present invention relates to polypeptides useful for detecting and

targeting primary receptors on endothelial cells for VEGF, i.e., VEGF receptor 2, also known as kinase domain region (KDR) and fetal liver kinase-1 (Flk-1), and for imaging and targeting complexes formed by VEGF and KDR. The involvement of VEGF and KDR in angiogenesis makes the VEGF/KDR and KDR binding polypeptides of the present invention particularly useful for imaging important sites of angiogenesis, e. g., neoplastic tumors, for targeting substances, e.g., therapeutics, including radiotherapeutics, to such sites, and for treating certain disease states, including those associated with inappropriate angiogenesis. Disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a  $KD < 1 \mu M$ ).

AN 2003:719271 HCAPLUS <<LOGINID::20080616>>

DN 139:265740

TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

IN Sato, Aaron K.; Sexton, Daniel J.; Ladner, Robert C.; Dransfield, Daniel T.; Swenson, Rolf E.; Marinelli, Edmund R.; Ramalingam, Kondareddiar; Nunn, Adrian D.; Von Wronski, Mathew A.; Shrivastava, Ajay; Pochon, Sibylle; Bussat, Philippe; Arbogast, Christophe; Pillai, Radhakrishna; Fan, Hong; Linder, Karen E.; Song, Bo; Nanjappan, Palaniappa

PA Dyax Corp., USA; Bracco International B.V.; et al.

SO PCT Int. Appl., 350 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 6



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003074005	A2	20030912	WO 2003-US6731	20030303 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2477836	A1	20030912	CA 2003-2477836	20030303 <--
	AU 2003213730	A1	20030916	AU 2003-213730	20030303 <--
	EP 1572724	A2	20050914	EP 2003-711418	20030303 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514915	T	20060518	JP 2003-572527	20030303 <--
	CA 2513044	A1	20040805	CA 2003-2513044	20030911
	WO 2004065621	A1	20040805	WO 2003-US28787	20030911 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003278807	A1	20040813	AU 2003-278807	20030911
	US 20050100963	A1	20050512	US 2003-661156	20030911 <--
	EP 1587944	A1	20051026	EP 2003-770325	20030911
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

	US 20050250700	A1	20051110	US 2004-939890	20040913 <--
	US 20080107607	A1	20080508	US 2006-608395	20061208 <--
PRAI	US 2002-360851P	P	20020301	<--	
	US 2003-440411P	P	20030115		
	US 2003-382082	A	20030303		
	WO 2003-US6731	W	20030303		
	US 2003-661156	A2	20030911		
	WO 2003-US28787	W	20030911		
	US 2005-749240P	P	20051209		
	US 2006-833342P	P	20060725		
OS	MARPAT 139:265740				
IT	599211-70-8P 599211-95-7P				
	RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy)				
RN	599211-70-8 HCAPLUS				
CN	L-Lysinamide, N-acetyl-L-valyl-L-cysteinyl-L-tryptophyl-L- $\alpha$ -glutamyl-L- $\alpha$ -aspartyl-L-seryl-L-tryptophylglycylglycyl-L- $\alpha$ -glutamyl-L-valyl-L-cysteinyl-L-phenylalanyl-L-arginyl-L-tyrosyl-L- $\alpha$ -aspartyl-L-prolylglycylglycylglycyl-N6-[O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\alpha$ -D-galactopyranosyl]-L-serylglycyl-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\alpha$ -D-galactopyranosyl]-L-seryl]-, cyclic (2 $\rightarrow$ 12)-disulfide (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A






PAGE 1-D




PAGE 2-A

Ph

PAGE 2-B



PAGE 2-C




RN 599211-95-7 HCAPLUS  
CN L-Lysinamide, N-acetyl-L-valyl-L-cysteinyl-L-tryptophyl-L- $\alpha$ -glutamyl-




L- $\alpha$ -aspartyl-L-seryl-L-tryptophylglycylglycyl-L- $\alpha$ -glutamyl-L-valyl-L-cysteinyl-L-phenylalanyl-L-arginyl-L-tyrosyl-L- $\alpha$ -aspartyl-L-prolylglycylglycylglycyl-N6-[N-[5-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,5-dioxopentyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\alpha$ -D-galactopyranosyl]-L-serylglycyl-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\alpha$ -D-galactopyranosyl]-L-seryl]-, cyclic (2 $\rightarrow$ 12)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




PAGE 2-A

Ph

PAGE 2-B




PAGE 2-C




L13 ANSWER 5 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Synthesis of monosulfated saccharides in the spacered form  
 AB The sulfated (Su) saccharides 3-Su-Gal $\beta$ , 3-Su-GalNAc $\beta$ ,  
 4-Su-GalNAc $\beta$ , 6-Su-GalNAc $\alpha$ , 6-Su-GlcNAc $\beta$ ,  
 6-Su-LacNAc $\beta$ , 6'-Su-LacNAc $\beta$ , 3'-Su-Gal $\beta$ 1-3GlcNAc $\beta$  and  
 3'-Su-Gal $\beta$ 1-3GalNAc $\alpha$ , all monosaccharides in  
 D-configuration, have been synthesized in the form of 3-aminopropyl or  
 3-trifluoroacetamidopropyl glycosides.  
 AN 2003:198768 HCAPLUS <<LOGINID::20080616>>  
 DN 139:53232  
 TI Synthesis of monosulfated saccharides in the spacered form  
 AU Ovchinnikova, Tatyana V.; Shipova, Ekaterina V.; Sablina, Marina A.;  
 Pazynina, Galina V.; Popova, Inna S.; Tuzikov, Aleksandr B.; Bovin,  
 Nicolai V.  
 CS M. M. Shemyakin-Yu. A. Ovchinnikov Institute of Bioorganic Chemistry,  
 Russian Academy of Sciences, Moscow, 117997, Russia  
 SO Mendeleev Communications (2002), (6), 213-215  
 CODEN: MENCEX; ISSN: 0959-9436  
 PB Russian Academy of Sciences  
 DT Journal  
 LA English  
 OS CASREACT 139:53232  
 IT 121042-74-8  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of monosulfated 3-aminopropyl or 3-trifluoroacetamidopropyl  
 oligosaccharides)  
 RN 121042-74-8 HCAPLUS  
 CN Acetamide, N-[3-[[3-O-acetyl-2-(acetylamino)-2-deoxy-6-O-(phenylmethyl)-  
 $\beta$ -D-glucopyranosyl]oxy]propyl]-2,2,2-trifluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 546128-12-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of monosulfated 3-aminopropyl or 3-trifluoroacetamidopropyl  
 oligosaccharides)  
 RN 546128-12-5 HCAPLUS  
 CN Acetamide, N-[3-[[3-O-acetyl-2-(acetylamino)-2-deoxy-6-O-(phenylmethyl)-  
 $\beta$ -D-galactopyranosyl]oxy]propyl]-2,2,2-trifluoro- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 6 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI D-Glucose as a multivalent chiral scaffold for combinatorial chemistry  
 AB Due to their high d. of functional groups and their availability in a variety of diastereomeric forms, monosaccharides are considered attractive scaffolds for combinatorial chemical that allow the attachment and defined spatial alignment of up to five different pharmacophoric groups. For their application in combinatorial syntheses on solid phase, a set of selectively removable hydroxy protecting groups in combination with a cleavable anchor is required. Herein, we report on the construction and use of a versatile multivalent glucose building block for parallel synthesis on the solid phase.  
 AN 2002:862528 HCAPLUS <<LOGINID::20080616>>  
 DN 138:287884  
 TI D-Glucose as a multivalent chiral scaffold for combinatorial chemistry  
 AU Opatz, Till; Kallus, Christopher; Wunberg, Tobias; Schmidt, Wolfgang; Henke, Stefan; Kunz, Horst  
 CS Institut fur Organische Chemie, Universitat Mainz, Mainz, 55128, Germany  
 SO Carbohydrate Research (2002), 337(21-23), 2089-2110  
 CODEN: CRBRAT; ISSN: 0008-6215  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 138:287884  
 IT 505077-81-6P 505077-83-8P 505077-85-0P  
 505077-86-1P 505077-88-3P 505077-90-7P  
 505077-91-8P 505077-93-0P 505077-95-2P  
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)  
 (combinatorial preparation of alkylglycosides using D-glucose as a multivalent chiral synthon)  
 RN 505077-81-6 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, butyl 2-O-butyl-3-O-propyl-, 6-[(2,4-difluorophenyl)carbamate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 505077-83-8 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, butyl 2-O-butyl-3-O-propyl-,  
 6-[(3-cyanophenyl)carbamate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 505077-85-0 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, butyl 2-O-butyl-3-O-propyl-,  
 6-[(4-methyl-3-nitrophenyl)carbamate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 505077-86-1 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, butyl 2-O-[(4-fluorophenyl)methyl]-3-O-propyl-,  
 6-[(2,4-difluorophenyl)carbamate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505077-88-3 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, butyl 2-O-[(4-fluorophenyl)methyl]-3-O-propyl-,  
6-[(3-cyanophenyl)carbamate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505077-90-7 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, butyl 2-O-[(4-fluorophenyl)methyl]-3-O-propyl-,  
6-[(4-methyl-3-nitrophenyl)carbamate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505077-91-8 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, butyl 2-O-[(2-methylphenyl)methyl]-3-O-propyl-, 6-[(2,4-difluorophenyl)carbamate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505077-93-0 HCAPLUS


CN  $\alpha$ -D-Glucopyranoside, butyl 2-O-[(2-methylphenyl)methyl]-3-O-propyl-, 6-[(3-cyanophenyl)carbamate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 505077-95-2 HCAPLUS  
CN  $\alpha$ -D-Glucopyranoside, butyl 2-O-[(2-methylphenyl)methyl]-3-O-propyl-,  
6-[(4-methyl-3-nitrophenyl)carbamate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 7 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Synthesis of tools for raising antibodies against moenomycin epitopes and  
initial immunological studies  
AB The moenomycins A and C1 as well as penta-, di- and monosaccharide  
analogs have been conjugated to BSA and biotin, resp. The moenomycin  
A-BSA conjugates have been used to raise polyclonal antibodies. It has  
been demonstrated that the antisera recognize moenomycin A.  
AN 2002:675350 HCAPLUS <<LOGINID::20080616>>  
DN 137:351070  
TI Synthesis of tools for raising antibodies against moenomycin epitopes and  
initial immunological studies  
AU Buchynskyy, Andriy; Stembera, Katherina; Knoll, Dietmar; Vogel, Stefan;  
Kempin, Uwe; Biallass, Astrid; Hennig, Lothar; Findeisen, Matthias;  
Muller, Dietrich; Welzel, Peter  
CS Institut fur Organische Chemie, Fakultat fur Chemie und Mineralogie,  
Universitat Leipzig, Leipzig, D-04103, Germany  
SO Tetrahedron (2002), 58(38), 7741-7760  
CODEN: TETRAB; ISSN: 0040-4020  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
IT 201666-58-2 303185-58-2 350582-97-7  
474903-27-0  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation and reaction of moenomycin analogs for biosynthesis of  
antibodies against moenomycin epitopes)  
RN 201666-58-2 HCAPLUS  
CN  $\alpha$ -D-Glucopyranuronamide, O-(5R)-5-C-[3-(3-carboxy-1-oxopropyl)-1-[3-  
[[ (2-mercaptoethyl) amino] carbonyl]-4-nitrophenyl]-1H-1,2,4-triazol-5-yl]-  
 $\alpha$ -L-arabinopyranosyl-(1 $\rightarrow$ 4)-O-2-(acetylamino)-2,6-dideoxy-  
 $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)-O-[ $\beta$ -D-glucopyranosyl-  
(1 $\rightarrow$ 6)]-O-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl-




(1→2)-4-C-methyl-, 3-carbamate 1-[(2R)-2-carboxy-2-[[ (2Z,6E,13E)-  
3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-nonadecatetraenyl]oxy]ethyl  
hydrogen phosphate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



PAGE 1-C


$\text{=CMe}_2$

PAGE 2-A



RN 303185-58-2 HCAPLUS  
CN  $\alpha$ -D-Glucopyranuronamide, O- $\beta$ -D-galactopyranuronamidosyl-  
(1 $\rightarrow$ 4)-O-2-(acetylamino)-2,6-dideoxy- $\beta$ -D-glucopyranosyl-  
(1 $\rightarrow$ 4)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 6)]-O-2-(acetylamino)-2-  
deoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 2)-4-C-methyl-, 3-carbamate  
1-[(2R)-2-carboxy-2-(2-oxoethoxy)ethyl hydrogen phosphate] (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.





 OH

 OH

RN 350582-97-7 HCAPLUS




CN  $\alpha$ -D-Glucopyranuronamide, O- $\beta$ -D-galactopyranuronamidoyl-  
 (1 $\rightarrow$ 4)-O-2-(acetylamino)-2,6-dideoxy- $\beta$ -D-glucopyranosyl-  
 (1 $\rightarrow$ 4)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 6)]-O-2-(acetylamino)-2-  
 deoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 2)-4-C-methyl-, 3-carbamate  
 1-[(2R)-2-carboxy-2-[2-(methylamino)ethoxy]ethyl hydrogen phosphate] (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 474903-27-0 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranuronamide, O-(5R)-5-C-[3-(3-carboxy-1-oxopropyl)-1-[3-  
 [[[2-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]ethyl]amino]carbonyl]-4-  
 nitrophenyl]-1H-1,2,4-triazol-5-yl]- $\alpha$ -L-arabinopyranosyl-  
 (1 $\rightarrow$ 4)-O-2-(acetamino)-2,6-dideoxy- $\beta$ -D-glucopyranosyl-  
 (1 $\rightarrow$ 4)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 6)]-O-2-(acetamino)-2-  
 deoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 2)-4-C-methyl-, 3-carbamate  
 1-[(2R)-2-carboxy-2-[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-  
 2,6,13,17-nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.








IT 261640-46-4P 474903-26-9DP, albumin conjugates  
 474903-28-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and reaction of moenomycin analogs for biosynthesis of  
 antibodies against moenomycin epitopes)

RN 261640-46-4 HCAPLUS

CN  $\alpha$ -D-Glucopyranuronamide, O-(5R)-5-C-[1-[3-[[2-aminoethyl)amino]carbonyl]-4-nitrophenyl]-3-(3-carboxy-1-oxopropyl)-1H-1,2,4-triazol-5-yl]- $\alpha$ -L-arabinopyranosyl-(1 $\rightarrow$ 4)-O-2-(acetylamino)-2,6-dideoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 6)]-O-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 2)-4-C-methyl-, 3-carbamate 1-[(2R)-2-carboxy-2-[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.






RN 474903-26-9 HCAPLUS

CN  $\alpha$ -D-Glucopyranuronamide, O-(5R)-5-C-[1-[3-[[[2-[[1-(2-carboxyethyl)-2,5-dioxo-3-pyrrolidinyl]thio]ethyl]amino]carbonyl]-4-nitrophenyl]-3-(3-carboxy-1-oxopropyl)-1H-1,2,4-triazol-5-yl]- $\alpha$ -L-arabinopyranosyl-(1→4)-O-2-(acetylamino)-2,6-dideoxy- $\beta$ -D-glucopyranosyl-(1→4)-O-[ $\beta$ -D-glucopyranosyl-(1→6)]-O-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl-(1→2)-4-C-methyl-, 3-carbamate 1-[(2R)-2-carboxy-2-[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.





PAGE 1-A



PAGE 1-B








RN 474903-28-1 HCAPLUS

CN Propanoic acid, 2-[2-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)methylamino]ethoxy]-3-[[[O-β-D-galactopyranuronamidosyl-(1→4)-O-2-(acetylamino)-2,6-dideoxy-β-D-glucopyranosyl-(1→4)-O-[β-D-glucopyranosyl-(1→6)]]-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-3-O-(aminocarbonyl)-4-C-methyl-α-D-glucopyranuronamidosyl]oxy]hydroxyphosphinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.






IT 474903-27-0DP, albumin conjugates 474903-28-1DP, albumin  
conjugates 474903-60-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and reaction of moenomycin analogs for biosynthesis of  
antibodies against moenomycin epitopes)  
RN 474903-27-0 HCAPLUS  
CN  $\alpha$ -D-Glucopyranuronamide, O-(5R)-5-C-[3-(3-carboxy-1-oxopropyl)-1-[3-  
[[[2-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]ethyl]amino]carbonyl]-4-  
nitrophenyl]-1H-1,2,4-triazol-5-yl]- $\alpha$ -L-arabinopyranosyl-  
(1 $\rightarrow$ 4)-O-2-(acetylamino)-2,6-dideoxy- $\beta$ -D-glucopyranosyl-  
(1 $\rightarrow$ 4)-O-[ $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 6)]-O-2-(acetylamino)-2-  
deoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 2)-4-C-methyl-, 3-carbamate  
1-[(2R)-2-carboxy-2-[[[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-  
2,6,13,17-nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




PAGE 1-B



PAGE 1-C




PAGE 2-A




RN 474903-28-1 HCAPLUS  
 CN Propanoic acid, 2-[2-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)methylamino]ethoxy]-3-[[[O-β-D-galactopyranuronamidosyl-(1→4)-O-2-(acetylamino)-2,6-dideoxy-β-D-glucopyranosyl-(1→4)-O-[β-D-glucopyranosyl-(1→6)]-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-3-O-(aminocarbonyl)-4-C-methyl-α-D-glucopyranuronamidosyl]oxy]hydroxyphosphinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A






RN 474903-60-1 HCAPLUS

CN 3,10,13,16-Tetraoxa-6,20-diazapentacosanoic acid, 2-[[[[[O-β-D-galactopyranuronamidoyl-(1→4)-O-2-(acetylamino)-2,6-dideoxy-β-D-glucopyranosyl-(1→4)-O-[β-D-glucopyranosyl-(1→6)]]-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-3-O-(aminocarbonyl)-4-C-methyl-α-D-glucopyranuronamidoyl]oxy]hydroxyphosphinyl]oxy]methyl]-25-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-21-oxo-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A












IT 76095-39-1DP, Moenomycin A, albumin conjugates  
 162895-32-1P, Moenomycin A12  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (synthesis of tools for raising antibodies against moenomycin epitopes  
 and initial immunol. studies)  
 RN 76095-39-1 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranuronamide, O-[N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-  
 $\beta$ -D-galactopyranuronamidoyl]-(1 $\rightarrow$ 4)-O-2-(acetylamino)-2,6-  
 dideoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)-O-[ $\beta$ -D-glucopyranosyl-  
 (1 $\rightarrow$ 6)]-O-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl-  
 (1 $\rightarrow$ 2)-4-C-methyl-, 3-carbamate 1-[(2R)-2-carboxy-2-[(2Z,6E,13E)-  
 3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-nonadecatetraen-1-  
 yl]oxy]ethyl hydrogen phosphate] (CA INDEX NAME)



Absolute stereochemistry.  
 Double bond geometry as shown.






RN 162895-32-1 HCAPLUS  
 CN  $\alpha$ -D-Galactopyranuronamide, O- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[O-[N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)- $\beta$ -D-galactopyranuronamidoyl]-(1 $\rightarrow$ 4)-2-(acetylamino)-2,6-dideoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 4)]-O-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 2)-, 3-carbamate 1-[(2R)-2-carboxy-2-[[ (2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX NAME)



Absolute stereochemistry.  
 Double bond geometry as shown.





RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Combinatorial libraries of glucosamine monosaccharides  
GI



II


AB The present invention provides a combinatorial synthesis of glucosamine monosaccharide I in which the monosaccharide ring is of the glucosamine or galactosamine configuration; R4 and R5 are hydrogen or together form an optionally substituted benzylidene acetal in which the optional substituent is chosen from halo, azido, alkoxy, nitro or alkyl; R3 is hydrogen; optionally substituted glycolate or optionally substituted lactate or derivs. thereof; or a carboxylic acid mimetic; R1 is optionally substituted acyl, optionally substituted benzoyl, optionally substituted biphenylcarbonyl, heteroaryl acyl, optionally substituted bicycloacyl, optionally substituted bicycloheteroacyl, sulfonamide, urea or carbamates; R2 is hydrogen; R1 and R2 together form succinimide, maleimide or optionally substituted phthalimide; R is N3, alkoxy, arylalkoxy, amine.

The invention also provides processes for the preparation of the compound of formula I and methods of screening for antibacterial or antibiotic compds. involving the compound of formula I. Thus, glucosamine II was prepared as potential antibacterial or antibiotic compound

AN 2002:314953 HCAPLUS <<LOGINID::20080616>>  
 DN 136:325779  
 TI Combinatorial libraries of glucosamine monosaccharides  
 IN West, Michaelleo; Meutermans, Wim; Adamson, George; Schafer, Karl; Schliebs, Darren  
 PA Alchemia Pty. Ltd., Australia  
 SO PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032915	A1	20020425	WO 2001-AU1307	20011017 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001095282	A	20020429	AU 2001-95282	20011017 <--
	EP 1326873	A1	20030716	EP 2001-975871	20011017 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AU 2001295282	B2	20061102	AU 2001-295282	20011017 <--
	US 20030232766	A1	20031218	US 2003-419070	20030417 <--
PRAI	AU 2000-797	A	20001017	<--	
	AU 2001-95282	A	20011017	<--	
	WO 2001-AU1307	W	20011017	<--	
OS	MARPAT 136:325779				
IT	412039-08-8P 412039-11-3P				
	RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)				
	(combinatorial libraries of glucosamine monosaccharides)				
RN	412039-08-8 HCAPLUS				
CN	$\beta$ -Normuramic acid, N-acetyl-1-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 412039-11-3 HCAPLUS  
CN  $\beta$ -Normuramic acid, N-(2,2-dimethyl-1-oxopropyl)-1-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L13 ANSWER 9 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI "Meshed-Bag Gathered-Bunch" Method for Solid-Phase Synthesis of Small Molecular Diverse Compounds  
AB A new "Meshed-Bag Gathered-Bunch" technol. for the solid-phase synthesis of peptide libraries was developed. Using this technol., the authors synthesized muramyl dipeptide mimetics including derivs. at the N- and C-terminus, cyclic muramyl dipeptide mimetics and muramyl dipeptide conjugates of tuftsin analogs. The advantages of this method include ease of manufacture, low unit cost of production, the phys. encoding method, and the compatibility with both parallel and "split-mix" approaches.  
AN 2002:73484 HCAPLUS <<LOGINID::20080616>>  
DN 136:263456  
TI "Meshed-Bag Gathered-Bunch" Method for Solid-Phase Synthesis of Small Molecular Diverse Compounds  
AU Zhang, Suo-De; Liu, Gang; Xia, Shu-Quan; Wu, Ping; Zhang, Liang  
CS Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China  
SO Journal of Combinatorial Chemistry (2002), 4(2), 131-137  
CODEN: JCCHFF; ISSN: 1520-4766  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 136:263456  
IT 405313-66-8P 405313-67-9P 405313-70-4P  
405313-71-5P 405313-72-6P 405313-73-7P  
405313-74-8P 405313-75-9P 405313-76-0P  
405313-77-1P 405313-78-2P 405313-79-3P  
405313-80-6P 405313-81-7P 405313-82-8P  
405313-83-9P 405313-84-0P 405313-85-1P  
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)  
("meshed-bag gathered-bunch" method-based solid-phase combinatorial synthesis of tuftsin peptide analogs, muramyl dipeptides and cyclic muramyl dipeptide mimetics)  
RN 405313-66-8 HCAPLUS  
CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 405313-67-9 HCAPLUS


CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-L-lysyl-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 405313-70-4 HCAPLUS

CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 405313-71-5 HCAPLUS




CN L-Lysine, N2-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-L-lysyl-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 405313-72-6 HCAPLUS

CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-L-threonyl-D- $\alpha$ -glutaminyl-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 405313-73-7 HCAPLUS

CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-threonyl-D-α-glutamyl-L-lysyl-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 405313-74-8 HCAPLUS

CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-L-threonyl-L-arginyl-L-prolyl-, 2-(phenylmethyl) ester


(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 405313-75-9 HCAPLUS


CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-D-α-glutamyl-L-lysyl-L-threonyl-L-arginyl-L-prolyl-, 1-(phenylmethyl) ester  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 405313-76-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-N6-glycyl-, (2→1')-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 405313-77-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-N6-β-alanyl-, (2→1')-lactam (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 405313-78-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-N6-(4-amino-1-oxobutyl)-, (2→3)-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 405313-79-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-N6-L-alanyl-, (2→1')-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 405313-80-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N6-D-alanyl-, (2 $\rightarrow$ 1')-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 405313-81-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N6-(L-alanyl-D- $\alpha$ -glutamyl)-, (2 $\rightarrow$ 1')-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N6-(D-alanyl-D- $\alpha$ -glutaminy)-, (2 $\rightarrow$ 1')-lactam  
(9CI) (CA INDEX NAME)

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N6-(L-alanyl-D- $\alpha$ -glutamyl)-, 2'-(phenylmethyl) ester, (2 $\rightarrow$ 1')-lactam (9CI) (CA INDEX NAME)

CC1=CC=C(C=C1)COc2cc(O)c(O)c(OC(=O)NC(C)C(=O)NC(C)C(=O)NCC3C(=O)NC(C)C(=O)N3)c2


Absolute stereochemistry.



RN	405313-85-1	HCAPLUS
CN	L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N6-(D-alanyl-L-glutaminy)-, (2 $\rightarrow$ 1')-lactam (9CI)	
	(CA INDEX NAME)	




Absolute stereochemistry.



RE.CNT 36      THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 10 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI New efficient route for synthesis of lipid A by using affinity separation  
AB New efficient synthesis of lipid A, an immunostimulating glycoconjugate of bacteria, was achieved for the construction of lipid A library by using synthesis based on affinity separation (SAS), where the compds. possessing a barbituric acid (BA)-tag are selectively and rapidly purified by interaction with an artificial receptor for BA. Glycosylation of a glycosyl acceptor possessing the BA-tag with a 4'-phosphorylated N-Troc glucosaminyl trichloroacetimidate gave the disaccharide 4'-phosphate, which was purified by the affinity separation. Successive removal of protective groups and introduction of acyl groups were then effected and the synthetic intermediate at each step was purified by the affinity separation. Cleavage of the tag and subsequent deprotection afforded Escherichia coli lipid A. SAS enabled the rapid preparation of lipid A, therefore, proved to be a promising method for synthesis of other complex glycoconjugates.  
AN 2001:829976 HCAPLUS <<LOGINID::20080616>>  
DN 136:200388  
TI New efficient route for synthesis of lipid A by using affinity separation  
AU Fukase, Yoshiyuki; Zhang, San-Qi; Iseki, Keiko; Oikawa, Masato; Fukase, Koichi; Kusumoto, Shoichi  
CS Department of Chemistry, Graduate School of Science, Osaka University, Osaka, 560-0043, Japan  
SO Synlett (2001), (11), 1693-1698  
CODEN: SYNLES; ISSN: 0936-5214  
PB Georg Thieme Verlag  
DT Journal  
LA English  
OS CASREACT 136:200388  
IT 400843-73-4P 400843-82-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(synthesis of Escherichia coli glycolipid A via glycosidation by using affinity separation)  
RN 400843-73-4 HCAPLUS  
CN  $\alpha$ -D-Glucopyranoside, 2-propen-1-yl 2-deoxy-4-O-[[4-[[5-[[3-[[4-[(5-ethylhexahydro-2,4,6-trioxo-5-pyrimidinyl)methyl]phenyl]methoxy]-3-oxopropyl]amino]-1,5-dioxopentyl]amino]phenyl]methyl]-2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400843-82-5 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, (1E)-1-propenyl 2-deoxy-6-O-(phenylmethyl)-2-  
 [[(2,2,2-trichloroethoxy)carbonyl]amino]-, 3-(2-propenyl carbonate) (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:07:06 ON 16 JUN 2008)

FILE 'REGISTRY' ENTERED AT 09:07:15 ON 16 JUN 2008

L1 STRUCTURE UPLOADED  
 L2 50 S L1  
 L3 76450 S L1 SSS FULL  
 L4 STRUCTURE UPLOADED  
 L5 STRUCTURE UPLOADED

L6                   STRUCTURE UPLOADED  
L7           42345 S L4   SUB=L3 FULL  
L8           9767 S L5   SUB=L7 FULL  
L9           3925 S L6   SUB=L8 FULL

FILE 'CAPLUS' ENTERED AT 09:17:01 ON 16 JUN 2008  
L10           1698 S L9

FILE 'STNGUIDE' ENTERED AT 09:17:10 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:18:05 ON 16 JUN 2008  
L11           122010 S MONOSACCH? OR (BUILDING BLOCK) OR (LIBRARY)  
L12           196 S L10 AND L11  
L13           160 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 09:18:11 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:08 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:19:09 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:31 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:20:03 ON 16 JUN 2008

=> log hold		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	376.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 09:20:42 ON 16 JUN 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'STNGUIDE' AT 09:21:46 ON 16 JUN 2008  
FILE 'STNGUIDE' ENTERED AT 09:21:46 ON 16 JUN 2008  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	376.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

=>

=> file registry  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.12	376.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

FILE 'REGISTRY' ENTERED AT 09:22:10 ON 16 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0  
DICTIONARY FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Documents and Settings\eolson\My Documents\e-Red  
Folder\10524048\10524048mainonot.str

L14 STRUCTURE UPLOADED

=> d his

(FILE 'HOME' ENTERED AT 09:07:06 ON 16 JUN 2008)

FILE 'REGISTRY' ENTERED AT 09:07:15 ON 16 JUN 2008

L1 STRUCTURE UPLOADED  
L2 50 S L1  
L3 76450 S L1 SSS FULL  
L4 STRUCTURE UPLOADED  
L5 STRUCTURE UPLOADED  
L6 STRUCTURE UPLOADED  
L7 42345 S L4 SUB=L3 FULL  
L8 9767 S L5 SUB=L7 FULL  
L9 3925 S L6 SUB=L8 FULL

FILE 'CAPLUS' ENTERED AT 09:17:01 ON 16 JUN 2008

L10 1698 S L9

FILE 'STNGUIDE' ENTERED AT 09:17:10 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:18:05 ON 16 JUN 2008

L11 122010 S MONOSACCH? OR (BUILDING BLOCK) OR (LIBRARY)  
L12 196 S L10 AND L11  
L13 160 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 09:18:11 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:08 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:19:09 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:31 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:20:03 ON 16 JUN 2008

FILE 'REGISTRY' ENTERED AT 09:22:10 ON 16 JUN 2008

L14 STRUCTURE UPLOADED

=> s l14 sub=19

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 09:22:45 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 657 TO ITERATE

100.0% PROCESSED 657 ITERATIONS

337 ANSWERS

SEARCH TIME: 00.00.01

L15 337 SEA SUB=L9 SSS FUL L14

=> s 19 not l15

L16 3588 L9 NOT L15

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

43.02

419.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-8.00

FILE 'HCAPLUS' ENTERED AT 09:23:09 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25

FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

substance identification.

=> s l16

L17 1520 L16

=> s l17 and l13

L18 142 L17 AND L13

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.69

422.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-8.00

FILE 'STNGUIDE' ENTERED AT 09:23:32 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jun 13, 2008 (20080613/UP).


=> d l18 20 ti abs bib hitstr

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L18 ANSWER 20 OF 142 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Combinatorial solid-phase synthesis of multivalent cyclic neoglycopeptides

GI



AB The authors have synthesized an 18-member library of carbohydrate-substituted cyclic peptides of the type cyclo[Boc-Lys-Pro-Lys(R)-Ala-Pro-Gly-Leu-Glu]-Bal-NH<sub>2</sub> [BOC = (CH<sub>3</sub>)<sub>3</sub>COC(O); Bal = β-alanine; R = 2-acetylamino-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranosyl, which was connected via -(Z)-CH<sub>2</sub>CH:CHCH<sub>2</sub>OC(O)- linker to side-chain amino groups of the cyclic peptide]. Using split-mix bead solid-phase synthesis techniques, up to three R groups were introduced to the cyclic peptide to test for directed multivalent activity in lectin binding. The urethane-type linker for sugar attachment gave virtually quant. yield, and allowed cleavage of the sugars from the cyclic peptide scaffold to allow for automated microsequencing of the scaffold under standard conditions. Using H<sub>2</sub>C:CHCH<sub>2</sub>OC(O), OCH<sub>2</sub>CH:CH<sub>2</sub>, and Ddv (I) as protecting groups for, resp., the N-terminal Lys, the C-terminal Glu side-chain, and

the side-chain amino groups to be sugar-substituted, the synthesis allowed on-bead cyclization and side-chain substitution using selective deprotection reactions.

AN 2000:894358 HCAPLUS <<LOGINID::20080616>>  
DN 134:147847  
TI Combinatorial solid-phase synthesis of multivalent cyclic neoglycopeptides  
AU Wittmann, Valentin; Seeberger, Sonja  
CS Institut für Organische Chemie, Johann Wolfgang Goethe-Universität,  
Frankfurt, 60439, Germany  
SO Angewandte Chemie, International Edition (2000), 39(23),  
4348-4352  
CODEN: ACIEF5; ISSN: 1433-7851  
PB Wiley-VCH Verlag GmbH  
DT Journal  
LA English  
OS CASREACT 134:147847  
IT 324532-92-5DP, resin-bound  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of multivalent cyclic neoglycopeptides using solid-phase  
synthesis)  
RN 324532-92-5 HCAPLUS  
CN  $\beta$ -Alaninamide, N2-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N5-[[[(2Z)-4-  
[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl]oxy]-  
2-butenyl]oxy]carbonyl]-L-ornithylglycyl-L-alanyl-N6-[[[(2Z)-4-[[3,4,6-tri-  
O-acetyl-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl]oxy]-2-  
butenyl]oxy]carbonyl]-D-lysyl-N5-[[[(2Z)-4-[[3,4,6-tri-O-acetyl-2-  
(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl]oxy]-2-butenyl]oxy]carbonyl]-  
L-ornithyl-D-valyl-L- $\alpha$ -glutamyl-N-(3-hydroxy-9H-xanthen-9-yl)-,  
(8 $\rightarrow$ 1)-lactam (9CI) (CA INDEX NAME)



Absolute stereochemistry.  
Double bond geometry as shown.



PAGE 1-A

AcO

AcO







RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file stnguide  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.12	430.95

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-8.80

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 09:24:49 ON 16 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jun 13, 2008 (20080613/UP).

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	431.01
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.80

FILE 'REGISTRY' ENTERED AT 09:25:30 ON 16 JUN 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0  
 DICTIONARY FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\eolson\My Documents\e-Red  
 Folder\10524048\10524048not2.str



```

chain nodes :
8 9 12
ring nodes :
1 2 3 4 5 6
chain bonds :
1-8 8-9 9-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 4-5 5-6 8-9 9-12

```

G1:O,C

G2:C,S

G3:O,S,N

G4:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 12:CLASS

L19 STRUCTURE UPLOADED

=> s l19 sss full

FULL SEARCH INITIATED 09:26:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1437076 TO ITERATE

69.6% PROCESSED 1000000 ITERATIONS

726968 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1437076 TO 1437076

PROJECTED ANSWERS: 1041659 TO 1047757

L20 726968 SEA SSS FUL L19

=> s l19 sub=116

116 IS NOT A VALID L#

L-numbers must be in the range L1-L999.

ENTER SUBSET L# OR (END):116

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 09:26:53 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 1553 TO ITERATE

100.0% PROCESSED 1553 ITERATIONS

1328 ANSWERS

SEARCH TIME: 00.00.01

L21 1328 SEA SUB=L16 SSS FUL L19

=> s l16 not l21

L22 2260 L16 NOT L21

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

221.38

652.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-8.80

FILE 'HCAPLUS' ENTERED AT 09:27:22 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25  
FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l21  
L23 752 L21

=> s l18 and l21  
752 L21  
L24 96 L18 AND L21

=> file stnguide		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.69	655.08
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.80

FILE 'STNGUIDE' ENTERED AT 09:27:46 ON 16 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jun 13, 2008 (20080613/UP).

=>

=>


=> d l24 12-14 ti abs bib hitstr  
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y



L24 ANSWER 12 OF 96 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Synthesis of a building block for phosphonate analogs  
of moenomycin A12 from D-tartaric acid  
AB An approach for the synthesis of moenomycin A12 C-glycoside partial  
structures is reported based on allyltin chemical An approach for the  
synthesis of moenomycin A12 C-glycoside partial structures is reported  
based on allyltin chemical  
AN 2001:246287 HCAPLUS <<LOGINID::20080616>>  
DN 135:19848  
TI Synthesis of a building block for phosphonate analogs

of moenomycin A12 from D-tartaric acid  
 AU Zahra, J.; Hennig, L.; Findeisen, M.; Welzel, P.; Muller, D.; Sheldrick,  
 W. S.  
 CS Fakultat fur Chemie und Mineralogie Johannisallee 29, Universitat Leipzig,  
 Leipzig, D-04103, Germany  
 SO Tetrahedron Letters (2001), 42(16), 2969-2972  
 CODEN: TELEAY; ISSN: 0040-4039  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 135:19848  
 IT 162895-32-1P, moenomycin A12  
 RL: PNU (Preparation, unclassified); PREP (Preparation)  
 (synthesis of a building block for phosphonate  
 analogs of moenomycin A12 from D-tartaric acid)  
 RN 162895-32-1 HCAPLUS  
 CN  $\alpha$ -D-Galactopyranuronamide, O- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-  
 [O-[N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)- $\beta$ -D-  
 galactopyranuronamidoyl]-(1 $\rightarrow$ 4)]-2-(acetylamino)-2,6-dideoxy- $\beta$ -  
 D-glucopyranosyl-(1 $\rightarrow$ 4)]-O-2-(acetylamino)-2-deoxy- $\beta$ -D-  
 glucopyranosyl-(1 $\rightarrow$ 2)-, 3-carbamate 1-[(2R)-2-carboxy-2-  
 [(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-  
 nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A





RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 13 OF 96 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Combinatorial solid-phase synthesis of multivalent cyclic neoglycopeptides  
GI





AB The authors have synthesized an 18-member library of carbohydrate-substituted cyclic peptides of the type cyclo[Boc-Lys-Pro-Lys(R)-Ala-Pro-Gly-Leu-Glu]-Bal-NH<sub>2</sub> [BOC = (CH<sub>3</sub>)<sub>3</sub>COC(O); Bal = β-alanine; R = 2-acetylamino-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranosyl, which was connected via -(Z)-CH<sub>2</sub>CH:CHCH<sub>2</sub>OC(O)- linker to side-chain amino groups of the cyclic peptide]. Using split-mix bead solid-phase synthesis techniques, up to three R groups were introduced to the cyclic peptide to test for directed multivalent activity in lectin binding. The urethane-type linker for sugar attachment gave virtually quant. yield, and allowed cleavage of the sugars from the cyclic peptide scaffold to allow for automated microsequencing of the scaffold under standard conditions. Using H<sub>2</sub>C:CHCH<sub>2</sub>OC(O), OCH<sub>2</sub>CH:CH<sub>2</sub>, and Ddv (I) as protecting groups for, resp., the N-terminal Lys, the C-terminal Glu side-chain, and the side-chain amino groups to be sugar-substituted, the synthesis allowed on-bead cyclization and side-chain substitution using selective deprotection reactions.



AN 2000:894358 HCAPLUS <<LOGINID::20080616>>  
 DN 134:147847  
 TI Combinatorial solid-phase synthesis of multivalent cyclic neoglycopeptides  
 AU Wittmann, Valentin; Seeberger, Sonja  
 CS Institut für Organische Chemie, Johann Wolfgang Goethe-Universität,  
 Frankfurt, 60439, Germany  
 SO Angewandte Chemie, International Edition (2000), 39(23),  
 4348-4352  
 CODEN: ACIEF5; ISSN: 1433-7851  
 PB Wiley-VCH Verlag GmbH  
 DT Journal  
 LA English  
 OS CASREACT 134:147847  
 IT 324532-92-5DP, resin-bound  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of multivalent cyclic neoglycopeptides using solid-phase  
 synthesis)  
 RN 324532-92-5 HCAPLUS  
 CN β-Alaninamide, N<sup>2</sup>-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N<sup>5</sup>-[[[(2Z)-4-  
 [[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-  
 2-butenyl]oxy]carbonyl]-L-ornithylglycyl-L-alanyl-N<sup>6</sup>-[[[(2Z)-4-[[3,4,6-tri-  
 O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-2-  
 butenyl]oxy]carbonyl]-D-lysyl-N<sup>5</sup>-[[[(2Z)-4-[[3,4,6-tri-O-acetyl-2-  
 (acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-2-butenyl]oxy]carbonyl]-  
 L-ornithyl-D-valyl-L-α-glutamyl-N-(3-hydroxy-9H-xanthen-9-yl)-,  
 (8→1)-lactam (9CI) (CA INDEX NAME)



Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A

AcO

AcO






RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L24 ANSWER 14 OF 96 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Parallel synthesis of muramyl peptides derivatives  
 AB A symposium report. 46 N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP) derivs. in which organic acids were sep. linked to the C terminal of MDP or to the C terminal of MDP's isomer N-acetyl isomuramyl-L-alanyl-D-isoglutamine through a bridge were prepared for study of structure-activity relationship. The small library of MDP derivs. on solid phase with multipin kits was constructed.  
 AN 2000:842865 HCAPLUS <<LOGINID::20080616>>  
 DN 134:178795  
 TI Parallel synthesis of muramyl peptides derivatives  
 AU Zhang, Suo-De; Liu, Gang; Xia, Su-Quan; Ding, Zhen-Kai  
 CS Institute of Pharmacology and Toxicology, Academy of Military Medical Science, Beijing, 100850, Peop. Rep. China  
 SO Peptides: Biology and Chemistry, Proceedings of the Chinese Peptide Symposium, 5th, Lanzhou, China, July 14-17, 1998 (2000), Meeting Date 1998, 198-201. Editor(s): Hu, Xiao-Yu; Wang, Rui; Tam, James P. Publisher: Kluwer Academic Publishers, Dordrecht, Neth. CODEN: 69AQX6  
 DT Conference  
 LA English  
 IT 15892-26-9 39524-05-5  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (solid phase synthesis of muramyl peptides derivs.)  
 RN 15892-26-9 HCAPLUS  
 CN  $\alpha$ -Muramic acid, N-acetyl-1-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39524-05-5 HCAPLUS  
 CN  $\alpha$ -Isomuramic acid, N-acetyl-1-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 325728-17-4P 325728-18-5P 325728-19-6P  
 325728-20-9P 325728-21-0P 325728-22-1P  
 325728-23-2P 325728-24-3P 325728-25-4P  
 325728-26-5P 325728-27-6P 325728-28-7P  
 325728-29-8P 325728-30-1P 325728-31-2P  
 325728-32-3P 325728-33-4P 325728-34-5P  
 325728-35-6P 325728-36-7P 325728-37-8P  
 325728-38-9P 325728-39-0P 325728-40-3P  
 325728-41-4P 325728-42-5P 325728-43-6P  
 325728-44-7P 325728-45-8P 325728-46-9P  
 325728-47-0P 325728-48-1P 325728-49-2P  
 325728-50-5P 325728-51-6P 325728-52-7P  
 325728-53-8P 325728-54-9P 325728-55-0P  
 325728-56-1P 325728-57-2P 325728-58-3P  
 325728-59-4P 325728-60-7P 325728-61-8P  
 325728-62-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (solid phase synthesis of muramyl peptides derivs.)


RN 325728-17-4 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[1-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-18-5 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D-α-glutaminy1-N6-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 325728-19-6 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-(1H-indol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-20-9 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-(1H-benzimidazole-2-carbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-21-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy]-N6-[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-22-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[2-(acetyloxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-23-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(1H-indazol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B




RN 325728-24-3 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-25-4 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(9H-xanthen-9-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-26-5 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-27-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-28-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(3-methylbenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-29-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[3-(3-nitrophenyl)-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B





RN 325728-30-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(2-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-31-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(1-oxo-3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 325728-32-3 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[ [3,4-dihydro-4-oxo-3-[4-(phenylmethoxy)phenyl]-7-quinazolinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-33-4 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[2-(2,5-dioxo-1-pyrrolidinyl)-5-methoxybenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A





RN 325728-34-5 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -isomuramoyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.






RN 325728-35-6 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(hydroxydiphenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-36-7 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(3,4,5-trihydroxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-37-8 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-38-9 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(2-quinolinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-39-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N<sub>6</sub>-(1-oxo-2,4-hexadienyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A







RN 325728-40-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(diphenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-41-4 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-42-5 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-(3-hydroxy-1-oxobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-43-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(2-[1,1'-biphenyl]-4-yl-1-oxohexyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-44-7 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(9-anthracenylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-45-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-(hydroxyphenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-46-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-47-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-[(9-hydroxy-9H-fluoren-9-yl)carbonyl]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-48-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N6-(2-iodobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-49-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[[1-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-50-5 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-51-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-(1H-indol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-52-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
 $\alpha$ -glutaminy-N6-(1H-benzimidazole-2-carbonyl)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.




RN 325728-53-8 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
 $\alpha$ -glutaminy-N6-(9H-xanthen-9-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-54-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N6-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-55-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
α-glutaminyl-N6-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-56-1 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
α-glutaminyl-N6-[(2R)-2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-57-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[2-(acetyloxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-58-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(1H-indazol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-59-4 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A



PAGE 1-B





RN 325728-60-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
α-glutamyl-N6-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-61-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-(2-quinolinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 325728-62-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-(1-oxo-2,4-hexadienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.24	674.42

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-11.20

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 09:30:37 ON 16 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0  
DICTIONARY FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\eolson\My Documents\e-Red Folder\10524048\10524048mainonot2.str

L25        STRUCTURE UPLOADED

=> s l25

SAMPLE SEARCH INITIATED 09:30:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -    197806 TO ITERATE

1.0% PROCESSED        2000 ITERATIONS                            50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*INCOMPLETE\*\*  
                              BATCH    \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS:        3929988 TO    3982252  
PROJECTED ANSWERS:            291366 TO    306008

L26            50 SEA SSS SAM L25

=> d his

(FILE 'HOME' ENTERED AT 09:07:06 ON 16 JUN 2008)

FILE 'REGISTRY' ENTERED AT 09:07:15 ON 16 JUN 2008

L1            STRUCTURE UPLOADED  
L2            50 S L1  
L3            76450 S L1 SSS FULL  
L4            STRUCTURE UPLOADED  
L5            STRUCTURE UPLOADED  
L6            STRUCTURE UPLOADED  
L7            42345 S L4    SUB=L3 FULL  
L8            9767 S L5    SUB=L7 FULL  
L9            3925 S L6    SUB=L8 FULL

FILE 'CAPLUS' ENTERED AT 09:17:01 ON 16 JUN 2008  
L10           1698 S L9

FILE 'STNGUIDE' ENTERED AT 09:17:10 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:18:05 ON 16 JUN 2008  
L11           122010 S MONOSACCH? OR (BUILDING BLOCK) OR (LIBRARY)  
L12           196 S L10 AND L11  
L13           160 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 09:18:11 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:08 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:19:09 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:31 ON 16 JUN 2008

```

FILE 'STNGUIDE' ENTERED AT 09:20:03 ON 16 JUN 2008

FILE 'REGISTRY' ENTERED AT 09:22:10 ON 16 JUN 2008
L14      STRUCTURE UPLOADED
L15      337 S L14 SUB=L9 FULL
L16      3588 S L9 NOT L15

FILE 'HCAPLUS' ENTERED AT 09:23:09 ON 16 JUN 2008
L17      1520 S L16
L18      142 S L17 AND L13

FILE 'STNGUIDE' ENTERED AT 09:23:32 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:23:47 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:23:48 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:24:49 ON 16 JUN 2008

FILE 'REGISTRY' ENTERED AT 09:25:30 ON 16 JUN 2008
L19      STRUCTURE UPLOADED
L20      726968 S L19 SSS FULL
L21      1328 S L19 SUB=L16 FULL
L22      2260 S L16 NOT L21

FILE 'HCAPLUS' ENTERED AT 09:27:22 ON 16 JUN 2008
L23      752 S L21
L24      96 S L18 AND L21

FILE 'STNGUIDE' ENTERED AT 09:27:46 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:28:13 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:28:15 ON 16 JUN 2008

FILE 'REGISTRY' ENTERED AT 09:30:37 ON 16 JUN 2008
L25      STRUCTURE UPLOADED
L26      50 S L25

=> s l26 sub=12
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full
FULL SUBSET SEARCH INITIATED 09:31:21 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED      11 ITERATIONS      7 ANSWERS
SEARCH TIME: 00.00.01


L27      7 SEA SUB=L2 SSS FUL L25

=> d l27 scan

L27  7 ANSWERS  REGISTRY  COPYRIGHT 2008 ACS on STN
IN    $\alpha$ -D-Mannopyranoside, phenylmethyl 2-(acetylamino)-2-deoxy-,
      3-acetate
MF   C17 H23 N O7

Absolute stereochemistry.

```



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2



L27 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN L-Serinamide, N-acetyl-L-leucyl-L-tyrosyl-L-arginyl-L-alanyl-L-  
 histidylglycyl-L-valyl-L-leucyl-O-[2-(acetylamino)-2-deoxy- $\beta$ -D-  
 glucopyranosyl]-L-seryl-L-cysteinylglycyl-L-tyrosyl-  
 SQL 13  
 MF C73 H112 N20 O23 S

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*



L27 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
 IN L-Aspartic acid, L-arginyl-L-valyl-L-seryl-O-[2-(acetylamino)-2-deoxy-  
 $\beta$ -D-glucopyranosyl]-L-seryl-L-glutaminyll-L- $\alpha$ -aspartyl-L-  
 tyrosylglycyl-L-arginyl-  
 SQL 10  
 MF C55 H88 N18 O24

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B







\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 122 not 17  
L28 0 L22 NOT L7

=> s 122 not 127  
L29 2260 L22 NOT L27

=> file hcaplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
44.86	719.28

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-11.20

CA SUBSCRIBER PRICE

FILE 'HCAPLUS' ENTERED AT 09:34:05 ON 16 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25  
FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s 129  
L30 872 L29

=> s 124 and 129  
872 L29  
L31 19 L24 AND L29

=> d 131 1-19 ti abs bib hitstr


L31 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Study of glycosylation with N-trichloroacetyl-D-glucosamine derivatives in the syntheses of the spacer-armed pentasaccharides sialyl lacto-N-neotetraose and sialyl lacto-N-tetraose, their fragments, and analogues  
AB The syntheses of 2-aminoethyl glycosides of the pentasaccharides Neu5Ac- $\alpha$ (2 $\rightarrow$ 3)-Gal- $\beta$ (1 $\rightarrow$ 4)-GlcNAc- $\beta$ (1 $\rightarrow$ 3)-Gal- $\beta$ (1 $\rightarrow$ 4)-Glc and Neu5Ac- $\alpha$ (2 $\rightarrow$ 3)-Gal- $\beta$ (1 $\rightarrow$ 3)-GlcNAc- $\beta$ (1 $\rightarrow$ 3)-Gal- $\beta$ (1 $\rightarrow$ 4)-Glc, their asialo di-, tri-, and tetrasaccharide fragments, and analogs included a systematic study of glycosylation with variously protected mono- and disaccharide donors derived from N-trichloroacetyl-D-glucosamine of galactose, lactose, and lactosamine glycosyl acceptors bearing benzoyl protection around the OH group to be glycosylated. Despite the low reactivity of these acceptors, stereospecificity and good to excellent yields were obtained with NIS-TfOH-activated thioglycoside donors of such type, or with AgOTf-activated glycosyl bromides, while other promoters, as well as a trichloroacetimidate donor, were less effective, and a  $\beta$ -acetate donor was inactive. In NIS-TfOH-promoted glycosylation with the thioglycosides, the use of TfOH in catalytic amount led to rapid formation of the corresponding oxazoline, but the quantity of TfOH necessary for further efficient coupling with an acceptor depended on the reactivity of the donor, varying from 0.07 equiv for a 3,6-di-O-benzylated monosaccharide derivative to 2.1 equiv for a peracetylated disaccharide one. In the glycosylation products, the N-trichloroacetyl group was easily converted into N-acetyl by alkaline hydrolysis followed by N-acetylation.  
AN 2001:780036 HCAPLUS <<LOGINID::20080616>>  
DN 136:184030  
TI Study of glycosylation with N-trichloroacetyl-D-glucosamine derivatives in the syntheses of the spacer-armed pentasaccharides sialyl lacto-N-neotetraose and sialyl lacto-N-tetraose, their fragments, and analogues  
AU Sherman, Andrei A.; Yudina, Olga N.; Mironov, Yury V.; Sukhova, Elena V.; Shashkov, Alexander S.; Menshov, Vladimir M.; Nifantiev, Nikolay E.  
CS N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, 119991, Russia  
SO Carbohydrate Research (2001), 336(1), 13-46  
CODEN: CRBRAT; ISSN: 0008-6215  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
OS CASREACT 136:184030  
IT 65730-00-9  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(study of glycosylation with N-trichloroacetylD-glucosamine derivs. in the syntheses of spacer-armed pentasaccharides)  
RN 65730-00-9 HCAPLUS  
CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 399035-90-6P 399036-09-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (study of glycosylation with N-trichloroacetylD-glucosamine derivs. in the syntheses of spacer-armed pentasaccharides)  
 RN 399035-90-6 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, ethyl 2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio-2-[(trichloroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 399036-09-0 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 2-propen-1-yl 2-(acetylamino)-2-deoxy-3-O-(phenylmethyl)-, 6-benzoate (CA INDEX NAME)


Absolute stereochemistry.



IT 399035-94-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (study of glycosylation with N-trichloroacetylD-glucosamine derivs. in the syntheses of spacer-armed pentasaccharides)  
 RN 399035-94-0 HCAPLUS


CN  $\beta$ -D-Glucopyranoside, ethyl O-2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactopyranosyl-(1 $\rightarrow$ 3)-O-[2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactopyranosyl-(1 $\rightarrow$ 6)]-2-deoxy-1-thio-2-[(trichloroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Preparation of oligosaccharide lipid-A analogs as antitumor and  
immunostimulating agents  
GI



AB New synthetic sugar Lipid-A analogs I wherein at least one of R1-R5 is selected from RCONHCH[R'NHCO]CH<sub>2</sub>CO-, RCH[X](CH<sub>2</sub>)<sub>m</sub>AOCHR'(CH<sub>2</sub>)<sub>n</sub>B-, RAOCHR'(CH<sub>2</sub>)<sub>m</sub>BOCHR''(CH<sub>2</sub>)<sub>n</sub>L-, where the remaining R1-R5 AR IDP H, R, COR, RCONHCH[R'NHCO]CH<sub>2</sub>CO-, RCH[X](CH<sub>2</sub>)<sub>m</sub>AOCHR'(CH<sub>2</sub>)<sub>n</sub>B-, RAOCHR'(CH<sub>2</sub>)<sub>m</sub>BOCHR''(CH<sub>2</sub>)<sub>n</sub>L-, RCH(X)(CH<sub>2</sub>)<sub>m</sub>A-, RAOCHR'(CH<sub>2</sub>)<sub>m</sub>B-, were each R, R', R'' is independently H, alkyl, A, B and L are independently selected from the group consisting of -CH-, -C(=O)- and -C(=S) groups; each X is independently selected from the group consisting of -OH, -SH, -NH, and-halogen; m and n are independently selected from the range of integers between 0 and 10 inclusive, X1 and X are -O- or -NH-, Y1 and Y2 are independently selected from the group consisting of -OH, -OP(O)(OH), -COOH, -OSOH, -CH(COOH) and -OP(O)(OH)(OCHCHNH), Z is H, -CHE, or -CHMG, where E is hydrogen, halogen, OH, NH, OSOH, SOH, P(O)(OH) or OP(O)(OH); M is -O-, -S-, -OC(=O), -SC(=O), -OC(=S)-, or -NHC(=O); G is -hydrogen, or a substituted or unsubstituted, branched or linear, saturated or unsatd. C-2 aliphatic hydrocarbon. or a physiol. acceptable salt thereof. Liposome

formulations containing totally synthetic components such as synthetic Lipid-A and synthetic lipopeptide derived from tumor-associated MUC1 mucin are described along with their therapeutic utility. Comparative test results of immunostimulating properties and toxicity of Lipid-A analogs are included. Thus, 2-deoxy-4-O-phosphono-2-[(3S)-3-tetradecanamido-4-nonylamino-4-oxo-butanamido]-3-O-tetradecanoyl-D-glucopyranose was prepared and tested in mice as antitumor and immunostimulating agent (CPM = m22).

AN 2001:380597 HCAPLUS <<LOGINID::20080616>>

DN 134:367137

TI Preparation of oligosaccharide lipid-A analogs as antitumor and immunostimulating agents

IN Jiang, Zi-Hua; Bach, Mimi; Yalamati, Damayanthi; Koganty, Rao; Longenecker, Michael

PA Biomira, Inc., Can.

SO PCT Int. Appl., 155 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001036433	A2	20010525	WO 2000-US31281	20001115 <--
	WO 2001036433	A3	20020510		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2396744	A1	20010525	CA 2000-2396744	20001115 <--
	AU 2001017647	A	20010530	AU 2001-17647	20001115 <--
	AU 780577	B2	20050407		
	EP 1232168	A2	20020821	EP 2000-980380	20001115 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003514824	T	20030422	JP 2001-538922	20001115 <--
PRAI	US 1999-164928P	P	19991115	<--	
	WO 2000-US31281	W	20001115	<--	
OS	MARPAT 134:367137				
IT	230966-79-7P 339316-72-2P 339316-86-8P 339316-91-5P 339316-94-8P 339317-06-5P 339317-13-4P 339317-21-4P 339317-29-2P 339317-37-2P 339317-38-3P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of oligosaccharide lipid A analogs as antitumor and immunostimulating agents)				
RN	230966-79-7 HCAPLUS				
CN	$\alpha$ -D-Glucopyranoside, 2-propenyl 2-deoxy-6-O-(phenylmethyl)-2-[[[2,2,2-trichloroethoxy]carbonyl]amino]-, 3-[(3R)-3-[(1-oxotetradecyl)oxy]tetradecanoate] (9CI) (CA INDEX NAME)				


Absolute stereochemistry. Rotation (+).



RN 339316-72-2 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, phenylmethyl 2-deoxy-2-[[ (3S)-4-(nonylamino)-1,4-dioxo-3-[(1-oxotetradecyl)amino]butyl]amino]-6-O-(phenylmethyl)-, 3-tetradecanoate (CA INDEX NAME)



Absolute stereochemistry. Rotation (+).



RN 339316-86-8 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-2-[[ (3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-6-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-2-[[ (3R)-1-oxo-3-[(1-oxohexadecyl)oxy]tetradecyl]amino]-3,4-bis-O-(phenylmethyl)- (CA INDEX NAME)



Absolute stereochemistry. Rotation (-).



RN 339316-91-5 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[ (3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-6-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-2-[[ (3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-3,4-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 339316-94-8 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-2-[[ (3S)-4-(nonylamino)-1,4-dioxo-3-[(1-oxotetradecyl)amino]butyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]- $\beta$ -D-glucopyranosyl]-2-[[ (3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-3,4-bis-O-(phenylmethyl)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).







RN 339317-06-5 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-6-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-(phenylmethyl)-3-O-2-propen-1-yl]- (CA INDEX NAME)



Absolute stereochemistry. Rotation (-).



RN 339317-13-4 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-2-[[ (3S)-4-(nonylamino)-1,4-dioxo-3-[(1-oxotetradecyl)amino]butyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-6-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-2-[[ (3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-(phenylmethyl)-, 3-[(3R)-3-(phenylmethoxy)tetradecanoate] (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 339317-21-4 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, phenylmethyl 2-deoxy-2-[[ (2,2,2-trichloroethoxy)carbonyl]amino]-, 3-[(3R)-3-(phenylmethoxy)tetradecanoate]  
(CA INDEX NAME)


Absolute stereochemistry.



RN 339317-29-2 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, 2-propen-1-yl 2-deoxy-6-O-(phenylmethyl)-2-[[ (2,2,2-trichloroethoxy)carbonyl]amino]-, 3-[(3R)-3-(dodecyloxy)tetradecanoate] (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 339317-37-2 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, phenylmethyl 2-deoxy-3-O-(phenylmethyl)-2-[[ (2,2,2-trichloroethoxy)carbonyl]amino]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 339317-38-3 HCAPLUS


CN  $\alpha$ -D-Glucopyranoside, phenylmethyl 2-deoxy-2-[[ (3R)-3-[[ (3R)-3-(dodecyloxy)-1-oxotetradecyl]oxy]-1-oxotetradecyl]amino]-3-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




L31 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Parallel synthesis of muramyl peptides derivatives  
 AB A symposium report. 46 N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP) derivs. in which organic acids were sep. linked to the C terminal of MDP or to the C terminal of MDP's isomer N-acetyl isomuramyl-L-alanyl-D-isoglutamine through a bridge were prepared for study of structure-activity relationship. The small library of MDP derivs. on solid phase with multipin kits was constructed.  
 AN 2000:842865 HCAPLUS <<LOGINID::20080616>>  
 DN 134:178795  
 TI Parallel synthesis of muramyl peptides derivatives  
 AU Zhang, Suo-De; Liu, Gang; Xia, Su-Quan; Ding, Zhen-Kai  
 CS Institute of Pharmacology and Toxicology, Academy of Military Medical Science, Beijing, 100850, Peop. China  
 SO Peptides: Biology and Chemistry, Proceedings of the Chinese Peptide Symposium, 5th, Lanzhou, China, July 14-17, 1998 (2000), Meeting Date 1998, 198-201. Editor(s): Hu, Xiao-Yu; Wang, Rui; Tam, James P. Publisher: Kluwer Academic Publishers, Dordrecht, Neth. CODEN: 69AQX6  
 DT Conference  
 LA English  
 IT 15892-26-9 39524-05-5  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (solid phase synthesis of muramyl peptides derivs.)  
 RN 15892-26-9 HCAPLUS  
 CN  $\alpha$ -Muramic acid, N-acetyl-1-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39524-05-5 HCAPLUS  
 CN  $\alpha$ -Isomuramic acid, N-acetyl-1-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 325728-17-4P 325728-18-5P 325728-19-6P  
 325728-20-9P 325728-21-0P 325728-22-1P  
 325728-23-2P 325728-24-3P 325728-25-4P  
 325728-26-5P 325728-27-6P 325728-28-7P  
 325728-29-8P 325728-30-1P 325728-31-2P  
 325728-32-3P 325728-33-4P 325728-34-5P  
 325728-35-6P 325728-36-7P 325728-37-8P  
 325728-38-9P 325728-39-0P 325728-40-3P  
 325728-41-4P 325728-42-5P 325728-43-6P  
 325728-44-7P 325728-45-8P 325728-46-9P  
 325728-47-0P 325728-48-1P 325728-49-2P  
 325728-50-5P 325728-51-6P 325728-52-7P  
 325728-53-8P 325728-54-9P 325728-55-0P  
 325728-56-1P 325728-57-2P 325728-58-3P  
 325728-59-4P 325728-60-7P 325728-61-8P  
 325728-62-9P


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (solid phase synthesis of muramyl peptides derivs.)


RN 325728-17-4 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -  
 glutaminyl-N6-[[1-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl]acetyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A





RN 325728-18-5 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 325728-19-6 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(1H-indol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-20-9 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(1H-benzimidazole-2-carbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A









RN 325728-21-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-22-1 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-[2-(acetyloxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-23-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N6-(1H-indazol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A





RN 325728-24-3 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 325728-25-4 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(9H-xanthen-9-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-26-5 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D-α-glutamyl-N6-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-27-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyln-6-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-28-7 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-(3-methylbenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-29-8 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N<sub>6</sub>-[3-(3-nitrophenyl)-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 325728-30-1 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(2-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-31-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(1-oxo-3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B




RN 325728-32-3 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy]-N6-[ [3,4-dihydro-4-oxo-3-[4-(phenylmethoxy)phenyl]-7-quinazolinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A









RN 325728-33-4 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-[2-(2,5-dioxo-1-pyrrolidinyl)-5-methoxybenzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 325728-34-5 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -  
 glutaminy-N6-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -isomuramoyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 325728-35-6 HCAPLUS  
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -  
 glutaminy-N6-(hydroxydiphenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-36-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-(3,4,5-trihydroxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-37-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-38-9 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-(2-quinolinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-39-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N6-(1-oxo-2,4-hexadienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A







RN 325728-40-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(diphenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-41-4 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-42-5 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-(3-hydroxy-1-oxobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-43-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-(2-[1,1'-biphenyl]-4-yl-1-oxohexyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-44-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-(9-anthracenylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A



PAGE 1-B





RN 325728-45-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(hydroxyphenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-46-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-47-0 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-[(9-hydroxy-9H-fluoren-9-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-48-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D-α-glutamyl-N6-(2-iodobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-49-2 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy]-N6-[[1-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
 $\alpha$ -glutaminyl-N6-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX  
 NAME)

PAGE 1-A





PAGE 1-B



CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
α-glutaminy-N6-(1H-indol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 325728-52-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
α-glutaminyl-N6-(1H-benzimidazole-2-carbonyl)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 325728-53-8 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
α-glutaminy-N6-(9H-xanthen-9-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-54-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
α-glutamyl-N6-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-55-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
α-glutaminy-N6-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-56-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-  
α-glutaminyl-N6-[(2R)-2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A



PAGE 1-B





RN 325728-57-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminyl-N6-[2-(acetyloxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-58-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(1H-indazol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-59-4 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-60-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutamyl-N6-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-61-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-(2-quinolinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-62-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- $\alpha$ -glutaminy1-N6-(1-oxo-2,4-hexadienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

L31 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
TI Efficient Synthesis of a Stereochemically Defined Carbohydrate Scaffold:  
Carboxymethyl 2-Acetamido-6-Azido- 4-O-Benzyl-2-deoxy- $\alpha$ -D-  
Glucopyranoside  
GI




AB The authors have described a highly efficient synthesis of a monosaccharide scaffold I with appropriate orientation of the functional group triad for the generation of broad spectrum libraries. Two keys steps in this synthesis are the regioselective ring opening of a benzylidene acetal to obtain the 4-O-benzyl derivative using H3B·NMe3/Me2BBr, and efficient oxidation of a 1-O-allyl to 1-O-carboxymethyl group in the presence of a benzyl ether as well as an azido functionality.

AN 2000:758802 HCAPLUS <<LOGINID::20080616>>


DN 134:56892  
 TI Efficient Synthesis of a Stereochemically Defined Carbohydrate Scaffold:  
 Carboxymethyl 2-Acetamido-6-Azido- 4-O-Benzyl-2-deoxy- $\alpha$ -D-  
 Glucopyranoside  
 AU Ghosh, Manuka; Dulina, Richard G.; Kakarla, Ramesh; Sofia, Michael J.  
 CS Intercardia Research Laboratories, Cranbury, NJ, 08852, USA  
 SO Journal of Organic Chemistry (2000), 65(24), 8387-8390  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 134:56892  
 IT 224964-75-4P 251324-18-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (efficient synthesis of carboxymethyl acetamidoazidobenzyl  
 deoxy- $\alpha$ -D-glucopyranoside, a stereochem. defined carbohydrate  
 scaffold)  
 RN 224964-75-4 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-6-O-  
 (phenylmethyl)-, 3-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 251324-18-2 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-4-O-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI combinatorial libraries and solid phase synthesis of glycosides and

## glycopeptides

GI



AB A compound of structure I wherein X is O or S; Z is O or NH; Y is COOH, COOR<sub>2</sub>, CH<sub>2</sub>OR<sub>3</sub>, CH<sub>3</sub>, or CH<sub>s</sub>Y<sub>2</sub>(3-s) where Y<sub>2</sub> is F, Cl, Br or I, and s is 0, 1, or 2 or Y and one of ZR<sub>4</sub> and OR<sub>5</sub> are linked to form a 6-membered cyclic acetal; Q = (CH<sub>2</sub>)<sub>n</sub>; p is 0 or 1; m is 0 or 1; n is 1 or 2. A library of compds. of structure II wherein X is O or S; Q = (CH<sub>2</sub>)<sub>n</sub>; A<sub>1</sub> is a residue of an α-amino acid attached through a terminal amino, a peptide residue comprising residues of from 2 to 10 α-amino acids and attached through a terminal amino, R<sub>1</sub> O, R<sub>1</sub>S, R<sub>1</sub>, R<sub>1</sub>NH or R<sub>1</sub>N-alkyl; A<sub>2</sub> is a residue of an α-amino acid attached through a terminal carboxyl, a peptide residue comprising residues of from 2 to 10 α-amino acids and attached through a terminal carboxyl, R<sub>2</sub>SO<sub>2</sub>, R<sub>2</sub>NHCO, R<sub>2</sub>OP(O)(OR<sub>6</sub>), R<sub>2</sub>P(O)(OR<sub>6</sub>) or R<sub>2</sub>, or A<sub>2</sub>, A<sub>3</sub> and N combine to form a nitrogen heterocycle; A<sub>3</sub> is hydrogen when A<sub>3</sub> is not combined with A<sub>2</sub> and N; A<sub>4</sub> is OR<sub>4</sub>, NHR<sub>4</sub>, CH<sub>2</sub>OR<sub>4</sub> or CH<sub>3</sub>; A<sub>5</sub> is O, NH or N-alkyl; p, q and r are independently 0 or 1; Y<sub>1</sub> and Y<sub>2</sub> are independently O or CH<sub>2</sub>; each of L<sub>1</sub> and L<sub>2</sub> is independently a difunctional alkyl, aryl, aralkyl, alkanoyl, aroyl or aralkanoyl group; L<sub>3</sub> is a single bond, CH<sub>2</sub>, carbonyl, OP(O)(OR<sub>7</sub>), NHP(O)(OR<sub>7</sub>), P(O)(OR<sub>7</sub>). Thus, solid phase preparation of Me 4-azido-4-deoxy-3-O-benzoyl-2'-O-carboxymethyl-α-D-fucopyranoside using peptide-bound resins is reported.

AN 1999:764164 HCAPLUS <<LOGINID::20080616>>

DN 132:12479

TI combinatorial libraries and solid phase synthesis of glycosides and glycopeptides

IN Sofia, Michael J.; Jain, Rakesh K.; Vaughan, Andrew; Gange, David M.; Ghosh, Manuka

PA Incara Pharmaceuticals Corp., USA

SO PCT Int. Appl., 106 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9961583	A2	19991202	WO 1999-US12032	19990528 <--
	WO 9961583	A3	20000406		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1998-87072P	P	19980528	<--	
OS	MARPAT 132:12479				
IT	224964-75-4P 251324-18-2P				
	RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (combinatorial libraries and solid phase synthesis of glycosides and glycopeptides)				
RN	224964-75-4	HCAPLUS			
CN	$\alpha$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-6-O- (phenylmethyl)-, 3-acetate (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 251324-18-2 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-4-O-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





TI Combinatorial library and solid-phase preparation of  
lipoglycopeptides as bactericides  
GI



I

AB Combinatorial library and solid-phase preparation of  
lipoglycopeptides of formula PSL (P = peptide; S = sugar, L = lipid) as  
bactericides are reported. Thus, lipoglycopeptide I was prepared and tested  
as protein bactericide (IC<sub>50</sub> = 2.4 .-. 0.2 µg/mL).

AN 1997:640561 HCAPLUS <<LOGINID::20080616>>

DN 127:293557

OREF 127:57387a,57390a

TI Combinatorial library and solid-phase preparation of  
lipoglycopeptides as bactericides

IN Sofia, Michael; Allanson, Nigel; Chen, Anna; Liu, Dashan; Chan, Tin Yau

PA Transcell Technologies, Inc., USA

SO PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9734623	A1	19970925	WO 1997-US4637	19970321 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2249323	A1	19970925	CA 1997-2249323	19970321 <--
	AU 9723411	A	19971010	AU 1997-23411	19970321 <--
	EP 934076	A1	19990811	EP 1997-916162	19970321 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000507246	T	20000613	JP 1997-533750	19970321 <--
PRAI	US 1996-13777P	P	19960321	<--	
	US 1996-24528P	P	19960826	<--	
	WO 1997-US4637	W	19970321	<--	
IT	196698-49-4P 196698-50-7P 196698-51-8P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)				
	(combinatorial library and solid phase preparation of lipoglycopeptides as bactericides)				

RN 196698-49-4 HCAPLUS

CN D-Alanine, N-(N-acetyl-1-O-dodecyl- $\beta$ -muramoyl)-L-alanyl-D- $\alpha$ -glutaminy-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

RN 196698-50-7 HCAPLUS

CN D-Alanine, N-(N-acetyl-1-O-dodecyl- $\beta$ -muramoyl)-L-alanyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196698-51-8 HCAPLUS


CN D-Alanine, N-(N-acetyl-1-O-dodecyl- $\beta$ -muramoyl)glycyl-D- $\alpha$ -glutaminy-L-lysyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT 63064-54-0P 196697-20-8P 196697-23-1P  
 196697-34-4P 196697-35-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (combinatorial library and solid phase preparation of  
 lipoglycopeptides as bactericides)  
 RN 63064-54-0 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-3,6-bis-O-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 196697-20-8 HCAPLUS  
 CN  $\alpha$ -Muramic acid, N-acetyl-1-O-2-propenyl-, methyl ester (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 196697-23-1 HCAPLUS  
 CN  $\alpha$ -Muramic acid, N-acetyl-1-O-2-propenyl-6-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl]-, methyl ester (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 196697-34-4 HCAPLUS  
 CN  $\alpha$ -Normuramic acid, N-acetyl-1-O-2-propenyl-, methyl ester (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 196697-35-5 HCAPLUS

CN  $\alpha$ -Normuramic acid, N-acetyl-1-O-2-propenyl-6-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 184910-81-4P 184910-82-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(combinatorial library and solid phase preparation of  
lipoglycopeptides as bactericides)

RN 184910-81-4 HCAPLUS

CN L-Alanine, N-[N-acetyl-1-O-[2-(dodecylamino)-2-oxoethyl]- $\alpha$ -muramoyl]-L-alanyl-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 184910-82-5 HCAPLUS

CN L-Alanine, N-[N-acetyl-6-O-[2-(acetilamino)-2-deoxy- $\beta$ -D-glucopyranosyl]-1-O-[2-(dodecylamino)-2-oxoethyl]- $\alpha$ -muramoyl]-L-alanyl-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L31 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Lipid A and related compounds. XXXIII. Synthesis and structure-activity relationships of N-acylated L-serine or L-threonine-containing D-glucosamine derivatives as mimics of lipid A disaccharide

GI



AB Four novel N-acylated L-serine or L-threonine-containing non-phosphorylated D-glucosamine derivs. structurally corresponding to the lipid A disaccharide backbone were synthesized. Compds. I (R1 = CH3, R2 = R3 = R4 = H; R1 = CH3, R2 = CH3(CH2)12CO, R3 = R4 = H; R1 = R2 = R3 = R4 = H) exhibited potent mitogenic activity. Among the threonine-linked lipid A analogs, serine-linked lipid A analogs, and homoserine-linked lipid A analogs, the serine compds. showed the most potent mitogenic activity.

AN 1997:427322 HCAPLUS <<LOGINID::20080616>>

DN 127:109122


OREF 127:21051a,21054a

TI Lipid A and related compounds. XXXIII. Synthesis and structure-activity relationships of N-acylated L-serine or L-threonine-containing D-glucosamine derivatives as mimics of lipid A disaccharide

AU Miyajima, Keisuke; Gomi, Noriaki; Ikeda, Kiyoshi; Achiwa, Kazuo


CS School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, 422,  
Japan  
SO Chemical & Pharmaceutical Bulletin (1997), 45(6), 1089-1093  
CODEN: CPBTAL; ISSN: 0009-2363  
PB Pharmaceutical Society of Japan  
DT Journal  
LA English  
IT 192462-69-4P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
study); PREP (Preparation)  
(synthesis and structure-activity relationships of N-acylated L-serine  
or L-threonine containing D-glucosamine derivs. as mimics of lipid A  
disaccharide)  
RN 192462-69-4 HCAPLUS  
CN L-Threonine, O-[2-deoxy-2-[[ (3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]  
amino]-3-O-(1-oxotetradecyl)- $\beta$ -D-glucopyranosyl]-N-(1-oxotetradecyl)-  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 192462-80-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(synthesis and structure-activity relationships of N-acylated L-serine  
or L-threonine containing D-glucosamine derivs. as mimics of lipid A  
disaccharide)  
RN 192462-80-9 HCAPLUS  
CN L-Threonine, O-[2-deoxy-2-[[ (3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]  
amino]-4,6-bis-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-N-(1-  
oxotetradecyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Substituted oligosaccharide as substrates and inhibitors for  
 glycosyltransferases and glycosidases and their enzymic synthesis  
 AB Substituted oligosaccharides that are substrates for some  
 glycosyltransferases and glycosidases and inhibitors for others are prepared  
 for use in the control of enzymic synthesis of oligosaccharides. The  
 system uses an acceptor saccharide; a donor monosaccharide; an  
 activating nucleotide suitable for the monosaccharide; an  
 activated donor monosaccharide regenerating system; a  
 pyrophosphate scavenger, and a glycosyltransferase. Several rounds of  
 enzymic synthesis can be conducted as necessary. (2R)-methyl-(3R,4R,5S)-  
 trihydroxypiperidine(I) was prepared by the aldolase-catalyzed reaction of  
 HCl-hydrolyzed (R)-3-azido-2-hydroxypropanal di-Et acetal and  
 dihydroxyacetone phosphate. I was then reduced with Pd in the presence of  
 HCHO to yield (1,2R)-dimethyl-(3R,4R,5S)-trihydroxypiperidine (II) or  
 oxidized with H2O2 to give (1,2R)-dimethyl-(3R,4R,5S)-trihydroxypiperidine  
 oxide (III). I inhibited brewer's yeast  $\alpha$ -glucosidase and sweet  
 almond  $\beta$ -glucosidase with Ki's of  $1.56 \times 10^{-3}$  and  $7.8 \times 10^{-4}$   
 M resp. II inhibited brewer's yeast  $\alpha$ -glucosidase and sweet almond  
 $\beta$ -glucosidase with Ki's of  $1.78 \times 10^{-3}$  and  $1.4 \times 10^{-4}$  M resp.  
 III inhibited brewer's yeast  $\alpha$ -glucosidase and sweet almond  
 $\beta$ -glucosidase with Ki's of  $6.95 \times 10^{-3}$  and  $1.49 \times 10^{-3}$  M  
 resp.

AN 1993:186950 HCAPLUS <<LOGINID::20080616>>

DN 118:186950

OREF 118:31992a

TI Substituted oligosaccharide as substrates and inhibitors for  
 glycosyltransferases and glycosidases and their enzymic synthesis

IN Wong, Chi Huey; Ichikawa, Yoshitaka; Shen, Gwo Jenn

PA Scripps Research Institute, USA

SO PCT Int. Appl., 157 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9216640	A1	19921001	WO 1992-US2178	19920317 <--
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	US 5278299	A	19940111	US 1991-670701	19910318 <--




CA	2106301	A1	19920919	CA	1992-2106301	19920317 <--
CA	2106301	C	19990406			
AU	9216680	A	19921021	AU	1992-16680	19920317 <--
AU	668505	B2	19960509			
EP	576592	A1	19940105	EP	1992-909519	19920317 <--
EP	576592	B1	20000531			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE						
JP	06505638	T	19940630	JP	1992-508819	19920317 <--
JP	3476455	B2	20031210			
AT	193551	T	20000615	AT	1992-909519	19920317 <--
US	5461143	A	19951024	US	1994-219242	19940329 <--
US	5593887	A	19970114	US	1995-476685	19950607 <--
US	5759823	A	19980602	US	1995-472877	19950607 <--
US	6168934	B1	20010102	US	1998-72958	19980505 <--
PRAI	US 1991-670701	A	19910318	<--		
	US 1991-707600	A	19910530	<--		
	US 1991-738211	A	19910730	<--		
	US 1992-852409	A	19920316	<--		
	WO 1992-US2178	A	19920317	<--		
	US 1992-889652	B1	19920526	<--		
	US 1994-219242	A3	19940329	<--		
	US 1995-472877	A1	19950607	<--		
OS	MARPAT 118:186950					
IT	67816-88-0P					
	RL: PREP (Preparation)					
	(preparation of, enzymic)					
RN	67816-88-0 HCAPLUS					
CN	$\alpha$ -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-3-O-2-propenyl-					
	(9CI) (CA INDEX NAME)					

Absolute stereochemistry.



IT	136882-32-1P 136882-33-2P 136882-34-3P
	RL: PREP (Preparation)
	(preparation of, in preparation oligosaccharides)
RN	136882-32-1 HCAPLUS
CN	$\beta$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-, 3-(methyl carbonate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136882-33-2 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-,  
3-(2-propenyl carbonate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136882-34-3 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-3-O-  
(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Building units of oligosaccharides. CIV. Synthesis of branched tetrasaccharide and pentasaccharide structures of N-glycoproteins methylated at 4'-OH of the branching unit.

AB The tetrasaccharide  $\alpha$ -D-Manp-(1  $\rightarrow$  3)[ $\alpha$ -D-Manp-(1  $\rightarrow$  6)]-4-O-methyl- $\beta$ -D-Manp-(1  $\rightarrow$  4)-D-GlcNAc and the pentasaccharide  $\beta$ -D-GlcpNAc-(1  $\rightarrow$  2)- $\alpha$ -D-Manp-(1  $\rightarrow$

3) [ $\alpha$ -D-Manp-(1  $\rightarrow$  6)]-4-O-methyl- $\beta$ -D-Manp-(1  $\rightarrow$  4)-D-GlcNAc were synthesized by adding the resp. functionalized building blocks. The compds. are useful for studies of the substrate specificities of GlcNAc transferases I and II in the biosynthesis of N-linked oligosaccharides, resp. In addition, an effective synthesis for the  $\beta$ -glycosidically linked building block  $\beta$ -D-Manp-(1  $\rightarrow$  4)- $\alpha$ -D-GlcpNAc was developed. The trichloroacetimidate method was particularly successful for synthesizing these glycosidic linkages.

AN 1993:59982 HCAPLUS <<LOGINID::20080616>>

DN 118:59982

OREF 118:10775a,10778a

TI Building units of oligosaccharides. CIV. Synthesis of branched tetrasaccharide and pentasaccharide structures of N-glycoproteins methylated at 4'-OH of the branching unit.

AU Paulsen, Hans; Wilkens, Roland; Brockhausen, Inka

CS Inst. Org. Chem., Univ. Hamburg, Hamburg, W-2000/13, Germany

SO Liebigs Annalen der Chemie (1992), (12), 1303-313

CODEN: LACHDL; ISSN: 0170-2041

DT Journal

LA English

OS CASREACT 118:59982

IT 55287-49-5


RL: RCT (Reactant); RACT (Reactant or reagent)

(glycosidation of, by benzyldeneglucopyranosyl trichloroacetimidate derivative)

RN 55287-49-5 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, phenylmethyl 2-(acetylamino)-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 143669-62-9P 143669-68-5P 143730-17-0P


143730-19-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as acetylglucosaminyl transferase substrate)


RN 143669-62-9 HCAPLUS

CN  $\alpha$ -D-Glucopyranose, O- $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 3)-O-[ $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 6)]-O-4-O-methyl- $\beta$ -D-mannopyranosyl-(1 $\rightarrow$ 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)





RN 143669-68-5 HCAPLUS

CN  $\alpha$ -D-Glucopyranose, O-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 2)-O- $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 3)-O-[ $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 6)]-O-4-O-methyl- $\beta$ -D-mannopyranosyl-(1 $\rightarrow$ 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)




RN 143730-17-0 HCAPLUS


CN  $\beta$ -D-Glucopyranose, O-2-(acetylamino)-2-deoxy- $\beta$ -D-glucopyranosyl-(1 $\rightarrow$ 2)-O- $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 3)-O-[ $\alpha$ -D-mannopyranosyl-(1 $\rightarrow$ 6)]-O-4-O-methyl- $\beta$ -D-mannopyranosyl-(1 $\rightarrow$ 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



L31 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Preparation of lipid A monosaccharide analogs as  
 immunostimulants and antitumor agents.  
 GI




AB The title compds. [I; one of R1,R4 = H, P(O)(OH)2, protecting group; the other = P(O)(OH)2; one of R2,R3 = (halo-, HO-, or C6-20 aliphatic acyloxy-substituted) C6-20 aliphatic acyl and the other = halo-, HO-, or C6-20 aliphatic acyloxy-substituted C6-20 aliphatic acyl, (halo-, HO-, or C6-20 aliphatic acyloxy-substituted) C6-20 alkyl], possessing macrophage-activating activity (no data), are prepared Thus, amidation of I (R1 = allyl, R2 = R3 = H, R4R5 = CMe2) (preparation given) with (R)-3-benzyloxymyristic acid in CH2Cl2 containing DCC followed by esterification with (±)-syn-2-fluoro-3-benzyloxycarboxyloxymyristic acid in CH2Cl2 containing DCC and 4-dimethylaminopyridine gave I [R1 = allyl, R2 = (R)-Me(CH2)10CH(OCH2Ph)CH2CO, R3 = (±)-Me(CH2)10CH(OCO2CH2Ph)CHFCO, R4R5 = CMe2]. The latter was treated with 1,5-cyclooctadiene-bis[methyldiphenylphosphine]iridium hexafluorophosphate and then H2, iodine, and pyridine to give I (R1 = H; R2-R5 = same as above) which was phosphorylated with (PhCH2O)2P(O)Cl in THF in the presence of BuLi followed by hydrogenolysis over 10% Pd/C to give I [R1 = P(O)(OH)2, R2 = (R)-Me(CH2)10CH(OH)CH2CO, R3 = (±)-Me(CH2)10CH(OH)CHFCO, R4 = R5 = H].  
 Addnl. 19 I were prepared  
 AN 1992:59901 HCAPLUS <<LOGINID::20080616>>  
 DN 116:59901  
 OREF 116:10385a,10388a

TI Preparation of lipid A monosaccharide analogs as  
 immunostimulants and antitumor agents.  
 IN Shiosaki, Masao; Ishida, Noboru; Kobayashi, Tomoo; Hiraoka, Tetsuo;  
 Akamatsu, Minoru; Nishijima, Masahiro  
 PA Sankyo Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 54 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 02256697	A	19901017	JP 1989-321153	19891211 <--
	JP 2839921	B2	19981224		
	DD 295854	A5	19911114	DD 1990-342041	19900625 <--
	SU 1836378	A3	19930823	SU 1990-4830600	19900625 <--
	CN 1052481	A	19910626	CN 1990-106805	19900626 <--
	CN 1029405	B	19950802		
	HU 55793	A2	19910628	HU 1990-3991	19900626 <--
	HU 217114	B	19991129		
	CZ 285583	B6	19990915	CZ 1990-3185	19900626 <--
	CA 2019972	A1	19910611	CA 1990-2019972	19900627 <--
	CA 2019972	C	20000808		
	EP 437016	A2	19910717	EP 1990-307045	19900627 <--
	EP 437016	B1	19960501		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	AT 137504	T	19960515	AT 1990-307045	19900627 <--
	ES 2088970	T3	19961001	ES 1990-307045	19900627 <--
	KR 187302	B1	19990401	KR 1990-9570	19900627 <--
	RU 2076107	C1	19970327	RU 1992-5052656	19920909 <--
	US 5792840	A	19980811	US 1994-280298	19940726 <--
	KR 183315	B1	19990401	KR 1998-37538	19980911 <--
PRAI	JP 1988-329964	A1	19881227	<--	
	JP 1989-321153	A	19891211	<--	
	JP 1990-37339	A	19900220	<--	
	US 1990-539605	B1	19900618	<--	
	KR 1990-9570	A	19900627	<--	
OS	MARPAT 116:59901				
IT	132760-36-2P 132760-38-4P 132760-39-5P 132760-45-3P 132760-46-4P 132760-50-0P 132791-86-7P 132791-89-0P 132791-91-4P 132791-94-7P 132791-95-8P 132792-02-0P 132792-04-2P 132792-05-3P 132828-16-1P 132831-92-6P 132881-14-2P 132882-51-0P 132882-54-3P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as intermediate for antitumor and immunostimulant lipid A analog)				
RN	132760-36-2 HCAPLUS				
CN	$\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3- [[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3- [[(phenylmethoxy)carbonyl]oxy]tetradecanoate], [2(2R,3S),3(R)]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 132760-38-4 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-(phenylmethoxy)tetradecanoate], [2(2S,3R),3(R)]- (9CI) (CA INDEX NAME)



RN 132760-39-5 HCAPLUS


CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-(phenylmethoxy)tetradecanoate] 6-(phenylmethyl carbonate), [2(2S,3R),3(R)]- (9CI) (CA INDEX NAME)



RN 132760-45-3 HCAPLUS


CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-, 3-tetradecanoate, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)






RN 132760-46-4 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-, 6-(phenylmethyl carbonate) 3-tetradecanoate, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)



RN 132760-50-0 HCAPLUS


CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-6-O-[(phenylmethoxy)methyl]-, 3-tetradecanoate, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)



RN 132791-86-7 HCAPLUS


CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[[[(phenylmethoxy)carbonyl]oxy]tetradecanoate] 6-(phenylmethyl carbonate), [2(2R,3S),3(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 132791-89-0 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] 6-(phenylmethyl carbonate), [2(2S,3R),3(R)]- (9CI) (CA INDEX NAME)



RN 132791-91-4 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate], [2(2R,3S),3(R)]- (9CI) (CA INDEX NAME)




RN 132791-94-7 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[1-oxo-3-

(phenylmethoxy)tetradecyl]amino]-3-O-[3-(phenylmethoxy)tetradecyl]-,  
[2(R),3(R)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 132791-95-8 HCAPLUS


CN  $\alpha$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[1-oxo-3-(phenylmethoxy)tetradecyl]amino]-6-O-[(phenylmethoxy)methyl]-3-O-[3-(phenylmethoxy)tetradecyl]-, [2(R),3(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 132792-02-0 HCAPLUS


CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-, 3-[3-(phenylmethoxy)tetradecanoate], [2(2R,3S),3(R)]- (9CI) (CA INDEX NAME)



RN 132792-04-2 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2,2-difluoro-1-oxo-3-[[ (phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 132792-05-3 HCAPLUS


CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2,2-difluoro-1-oxo-3-[[ (phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] 6-(phenylmethyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 132828-16-1 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-6-O-[(phenylmethoxy)methyl]-, 3-[3-(phenylmethoxy)tetradecanoate], [2(2S,3R),3(R)]- (9CI) (CA INDEX NAME)




RN 132831-92-6 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-, 3-tetradecanoate, [S-(R\*,S\*)]- (9CI)  
(CA INDEX NAME)




RN 132881-14-2 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] 6-(phenylmethyl carbonate), [2(2R,3S),3(R)]- (9CI) (CA INDEX NAME)




RN 132882-51-0 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate], [2(2S,3R),3(R)]- (9CI) (CA INDEX NAME)



RN 132882-54-3 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-6-O-[(phenylmethoxy)methyl]-, 3-[3-(phenylmethoxy)tetradecanoate], [2(2R,3S),3(R)]- (9CI) (CA INDEX NAME)



L31 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis of novel disaccharides based on glycosyltransferases:  
 $\beta$ -1,4-galactosyltransferase

AB  $\beta$ -1,4-Galactosyltransferase and  $\beta$ -galactosidase have been investigated with regard to their acceptor specificity and used in the synthesis of galactosides using 5-thioglucofucose, deoxyazaglucofucose, glucal, modified N-acetylglucosamine and glucose derivs. as acceptors.

AN 1991:680427 HCAPLUS <<LOGINID::20080616>>

DN 115:280427

OREF 115:47671a,47674a

TI Synthesis of novel disaccharides based on glycosyltransferases:  
 $\beta$ -1,4-galactosyltransferase

AU Wong, Chi Huey; Krach, Thomas; Gautheron-Le Narvor, Christine; Ichikawa, Yoshitaka; Look, Gary C.; Gaeta, Federico; Thompson, David; Nicolaou, K. C.

CS Dep. Chem., Scripps Res. Inst., La Jolla, CA, 92037, USA

SO Tetrahedron Letters (1991), 32(37), 4867-70

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English


IT 136882-31-0 136882-32-1 136882-33-2  
136882-34-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
(galactosidation of, enzymic)

RN 136882-31-0 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, butyl 2-(acetylamino)-2-deoxy-3-O-2-propenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136882-32-1 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-, 3-(methyl carbonate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136882-33-2 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-, 3-(2-propenyl carbonate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136882-34-3 HCAPLUS


CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-3-O-(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Selective pivaloylation of 2-(acetamido)-2-deoxy sugars [Erratum to document cited in CA110(23):213238k]  
 AB Errors in the names for compds. 8, 19, and 20 have been corrected The errors were reflected in the index entries.  
 AN 1989:614852 HCAPLUS <<LOGINID::20080616>>  
 DN 111:214852  
 OREF 111:35649a,35652a  
 TI Selective pivaloylation of 2-(acetamido)-2-deoxy sugars [Erratum to document cited in CA110(23):213238k]  
 AU Ljevakovic, Durdica; Tomic, Srdanka; Tomasic, Jelka  
 CS Dep. Radioimmunol., Inst. Immunol., Zagreb, 41000, Yugoslavia  
 SO Carbohydrate Research (1989), 191(1), C1  
 CODEN: CRBRAT; ISSN: 0008-6215  
 DT Journal  
 LA English  
 IT 3748-32-1 19229-53-9  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (pivaloylation of (Erratum))  
 RN 3748-32-1 HCAPLUS  
 CN  $\alpha$ -Muramic acid, N-acetyl-1-O-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 19229-53-9 HCAPLUS  
 CN  $\alpha$ -Isomuramic acid, N-acetyl-1-O-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.






IT 120489-44-3P 120489-47-6P 120489-56-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and acetylation of (Erratum))  
 RN 120489-44-3 HCAPLUS  
 CN α-D-Glucopyranose, 2-(acetyl-amino)-2-deoxy-, 1,3,6-tris(2,2-  
 dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




RN 120489-47-6 HCAPLUS  
 CN α-Muramic acid, N-acetyl-1-O-methyl-, methyl ester,  
 6-(2,2-dimethylpropanoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 120489-56-7 HCAPLUS  
 CN  $\beta$ -D-Glucopyranose, 2-(acetylamino)-2-deoxy-, 1,3,6-tris(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




IT 120489-33-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation, acetylation and enzymic hydrolysis of (Erratum))  
 RN 120489-33-0 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-,  
 3,6-bis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.





IT 120489-51-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation, acetylation, pivaloylation and enzymic hydrolysis of  
 (Erratum))  
 RN 120489-51-2 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-,  
 3,6-bis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Preparation of physiologically active lipid A analogs linked to  
 S-containing peptidoglycan analogs.  
 GI



AB The title compds. (I; R = Q; R<sub>1</sub> = R<sub>2</sub> = H; m, n = 8-12; p = 0-22; q = 1-15) (II) having physiol. activities (no data) were prepared Esterification of 2-(trimethylsilyl)ethyl 4-O-[bis(2,2,2-trichloroethyl)phosphono-2-deoxy-3-O-tetradecanoyl-2-[(3R)-3-tetradecanoyloxytetradecanamido]-β-D-glucopyranoside (III) (preparation given) with succinic anhydride in CH<sub>2</sub>Cl<sub>2</sub> containing 4-dimethylaminopyridine (DMAP) gave I (R = OH, OR<sub>1</sub> = β-Me<sub>3</sub>SiCH<sub>2</sub>CH<sub>2</sub>, R<sub>2</sub> = CCl<sub>3</sub>CH<sub>2</sub>, m = n = 12) which was treated with DCC in 1,4-dioxane containing concentrated H<sub>2</sub>SO<sub>4</sub> followed by N-acetylmuramic acid derivative QH (p = 0, q = 10) (IV) (preparation given) to give I (R = Q; OR<sub>1</sub>, R<sub>2</sub>, m, n, p,

q = same as above). Stepwise deprotection of the latter by treatment with BF<sub>3</sub>·OEt<sub>2</sub> in CH<sub>2</sub>Cl<sub>2</sub> to remove Me<sub>3</sub>SiCH<sub>2</sub>CH<sub>2</sub> group followed by treatment with Zn dust in AcOH to remove the CCl<sub>3</sub>CH<sub>2</sub> group gave I (R = Q, R<sub>1</sub> = R<sub>2</sub> = H, m = n = 12, p = 0, q = 10).

AN 1989:534690 HCAPLUS <<LOGINID::20080616>>

DN 111:134690

OREF 111:22563a,22566a

TI Preparation of physiologically active lipid A analogs linked to S-containing peptidoglycan analogs.

IN Hasegawa, Akira; Kiso, Makoto; Morihara, Kazuyuki

PA Toho Pharmaceutical Industries Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 8 pp.


CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63307896	A	19881215	JP 1987-144457	19870609 <--
PRAI	JP 1987-144457		19870609	<--	
OS	MARPAT 111:134690				
IT	86704-48-5		89137-05-3	89137-07-5	
	RL: RCT (Reactant); RACT (Reactant or reagent)				
	(esterification of, with (tert-butoxycarbonylamino)undecanoic acid)				
RN	86704-48-5	HCAPLUS			
CN	D- $\alpha$ -Glutamine, N2-[N-(N-acetyl-1-S-acetyl-1-thio- $\beta$ -muramoyl)-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)				




RN 89137-05-3 HCAPLUS

CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-(1-oxodecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 89137-07-5 HCAPLUS

D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-(1-oxooctadecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 122565-71-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and amidation of, with (carboxypropanoyl)glucosamine  
derivative)


RN 122565-71-3 HCAPLUS

CN	D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-(11-amino-1-oxoundecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, methyl ester, mono(trichloroacetate) (9CI) (CA INDEX NAME)
----	--

CM 1

CRN 122099-26-7


CMF C33 H57 N5 O12 S




CM 2

CRN 76-03-9

CMF C2 H C13 O2





IT 122078-63-1P 122078-86-8P 122501-68-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and deprotection of)  
 RN 122078-63-1 HCAPLUS  
 CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(1,1-  
 dimethylethoxy)carbonyl]amino]-1-oxoundecyl]-1-thio- $\beta$ -muramoyl]-L-  
 alanyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 122078-86-8 HCAPLUS  
 CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(3-carboxy-1-  
 oxopropyl)amino]-1-oxoundecyl]-1-thio- $\beta$ -muramoyl]-L-alanyl]-,  
 5-methyl ester, 6-ester with (R)-2-(trimethylsilyl)ethyl  
 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]- $\beta$ -D-  
 glucopyranoside 4-[bis(2,2,2-trichloroethyl) phosphate] 3-tetradecanoate  
 (9CI) (CA INDEX NAME)

PAGE 1-A





RN	122501-68-2	HCAPLUS	
CN	D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-thio- $\beta$ -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]- $\beta$ -D-glucopyranose 4-[bis(2,2,2-trichloroethyl) phosphate] 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)		




```

IT      122099-30-3P
      RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
      (Reactant or reagent)
      (preparation and selective silylation of, by tert-butyldimethylsilyl
      chloride)
RN      122099-30-3  HCAPLUS
CN       $\beta$ -D-Glucopyranoside, 2-(trimethylsilyl)ethyl 2-deoxy-2-[[1-oxo-3-[(1-
```


oxotetradecyl)oxy]tetradecyl]amino]-, 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 122501-63-7P 122501-64-8P 122501-65-9P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of, as drug)  
 RN 122501-63-7 HCAPLUS  
 CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-thio- $\beta$ -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]- $\beta$ -D-glucopyranose 4-(dihydrogen phosphate) 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B






RN 122501-64-8 HCAPLUS  
 CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-S-(1-oxodecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]- $\beta$ -D-glucopyranose 4-(dihydrogen phosphate) 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



RN 122501-65-9 HCAPLUS  
 CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-S-(1-oxooctadecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]- $\beta$ -D-glucopyranose 4-(dihydrogen phosphate) 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)

PAGE 1-A





L31 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of physiologically active congenates of lipid A nonreducing monosaccharide subunit analogs with 1-thiomuramyl dipeptide derivatives

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title conjugates [I; X = Q, R = R1 = H; l = 8-12; m = 0-22; n = 1-15; provided that the asym. C's at the 3-position of 2- or 3-substituents in the pyranose ring may have S- or R-configuration], having physiol. activity (no data), were prepared Treatment of I (X = OH, OR =  $\beta$ -OCH2CH2SiMe3, R1 = Cl3CCH2; l = 12) (II) (preparation given) with DCC and concentrated H2SO4 in 1,4-dioxane and reaction of the active intermediate with 1-thiomuramyl dipeptide derivative QH·CF3CO2H (m = 0, n = 10) in MeOH/1,4-dioxane containing Et3N gave 42.2% I (X = Q, OR =  $\beta$ -OCH2CH2SiMe3, R1 = Cl3CCH2, l = 12, m = 0, n = 10). Deprotection of the latter by treatment with BF3·OEt2 in Cl2H2 to remove Me3SiCH2CH2, followed by Zn powder to remove Cl3CCH2 in AcOH, gave I (X = Q, R = R1 = H, l = 12, m = 0, n = 10).

AN 1989:515701 HCAPLUS <<LOGINID::20080616>>

DN 111:115701

OREF 111:19407a,19410a

TI Preparation of physiologically active congenates of lipid A nonreducing monosaccharide subunit analogs with 1-thiomuramyl dipeptide derivatives

IN Hasegawa, Akira; Kiso, Makoto; Morihara, Kazuyuki

PA Toho Pharmaceutical Industries Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 01019098	A	19890123	JP 1987-175766	19870714 <--
PRAI	JP 1987-175766		19870714	<--	
OS	MARPAT 111:115701				
IT	122099-28-9				

RL: RCT (Reactant); RACT (Reactant or reagent)  
(amidation of, with (carboxypropanoyl)glucosamine derivative)

RN 122099-28-9 HCAPLUS

CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-6-O-(11-amino-1-oxoundecyl)-1-S-(1-oxodecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 122078-65-3 122331-26-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
(amidation of, with (carboxypropanoyl)glucosamine derivative, in preparation of drug)

RN 122078-65-3 HCAPLUS

CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-6-O-(11-amino-1-oxoundecyl)-1-S-(1-oxooctadecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 122331-26-4 HCAPLUS


CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-(11-amino-1-oxoundecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, methyl ester, mono(chloroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1



CRN 122099-26-7

CMF C33 H57 N5 O12 S

$$\begin{array}{c}
 \text{Me}_3\text{Si}-\text{CH}_2-\text{CH}_2-\text{O} \\
 | \\
 \text{Me}_3\text{Si}-\text{CH}_2-\text{CH}_2-\text{O} \\
 | \\
 \text{Me}-(\text{CH}_2)_{10}-\text{CH}-\text{CH}_2-\text{C}(=\text{O})-\text{NH} \\
 | \\
 \text{Me}-(\text{CH}_2)_{10}-\text{CH}-\text{CH}_2-\text{C}(=\text{O})-\text{O} \\
 | \\
 \text{Me}-(\text{CH}_2)_{12}-\text{C}(=\text{O})-\text{O}
 \end{array}$$



RN	122266-81-3	HCAPLUS
CN	D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-thio- $\beta$ -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 1,5-anhydro-2-deoxy-2-[(3-hydroxy-1-oxotetradecyl)amino]-D-glucitol 4-[bis(2,2,2-trichloroethyl) phosphate] 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate], [2(R),3(R)]- (9CI) (CA INDEX NAME)	




```

IT      122266-75-5P
        RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
        (Reactant or reagent)
        (preparation and selective silylation of, by tert-butyldimethylsilyl
        chloride)
RN      122266-75-5  HCAPLUS

```


CN  $\beta$ -D-Glucopyranoside, 2-(trimethylsilyl)ethyl 2-deoxy-2-[[1-oxo-3-[2-(trimethylsilyl)ethoxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate], [2(R),3(R)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





IT 122266-71-1P 122266-72-2P 122289-57-0P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of, as drug)  
 RN 122266-71-1 HCAPLUS  
 CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-thio- $\beta$ -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with [2(R),3(R)]-2-deoxy-2-[(3-hydroxy-1-oxotetradecyl)amino]- $\beta$ -D-glucopyranose 4-(dihydrogen phosphate) 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] (9CI) (CA INDEX NAME)

PAGE 1-A






RN	122266-72-2	HCAPLUS
CN	D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-S-(1-oxooctadecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with [2(R),3(R)]-2-deoxy-2-[(3-hydroxy-1-oxotetradecyl)amino]- $\beta$ -D-glucopyranose 4-(dihydrogen phosphate) 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] (9CI) (CA INDEX NAME)	




RN	122289-57-0	HCAPLUS
CN	D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-6-O-[11-[(3-carboxy-1-	

oxopropyl)amino]-1-oxoundecyl]-1-S-(1-oxodecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[(3-hydroxy-1-oxotetradecyl)amino]- $\beta$ -D-glucopyranose 4-(dihydrogen phosphate) 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate], [2(R),3(R)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L31 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Preparation of lipid A nonreducing monosaccharide analogs linked  
 to peptidoglycan thio analogs having physiological activity  
 GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. (I; R = R1 = H; X = Q; m, n = 8-12; p = 0-22; q = 1-15) (II) having physiol. activities (no data), were prepared Selective S-deacetylation of N-[[2-O-(2-acetamido-1-S-acetyl-2,3-dideoxy-4,6-isopropylidene-1-thio- $\beta$ -D-glucopyranosyl-3-yl)-D-lactoyl]]-L-alanyl-D-isoglutamine Me ester with NaOMe in MeOH at -20° followed by thioesterification with 11-(tert-butoxycarbonylamino)undecanoic acid in 1,4-dioxane containing DCC, deacetonation with 80% aqueous HOAc at 45°, and esterification with decanoic acid in dioxane containing DCC and a trace of





CMF C2 H C13 O2




```


IT      121885-15-2P 121885-18-5P 121885-20-9P
        RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
        (Reactant or reagent)
        (preparation and deprotection of)
RN      121885-15-2  HCAPLUS
CN      D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-[11-[[[(1,1-
        dimethylethoxy)carbonyl]amino]-1-oxoundecyl]-6-O-(1-oxodecyl)-1-thio-
         $\beta$ -muramoyl]-L-alanyl]-, methyl ester (9CI)  (CA INDEX NAME)

```

PAGE 1-A




PAGE 1-B




RN	121885-18-5	HCAPLUS
CN	D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-6-O-(1-oxodecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-(trimethylsilyl)ethyl 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]- $\beta$ -D-glucopyranoside 4-[bis(2,2,2-trichloroethyl) phosphate] 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 1-B




RN 121885-20-9 HCAPLUS  
 CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-6-O-(1-oxodecyl)-1-thio- $\beta$ -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]- $\beta$ -D-glucopyranose 4-[bis(2,2,2-trichloroethyl) phosphate] 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 1-B




IT 121885-14-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and esterification of, with decanoic acid)  
 RN 121885-14-1 HCAPLUS  
 CN D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-[11-[[[1,1-dimethylethoxy)carbonyl]amino]-1-oxoundecyl]-1-thio- $\beta$ -muramoyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)




```


IT      121897-87-8P
        RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
        study); PREP (Preparation); USES (Uses)
        (preparation of, as drug)
RN      121897-87-8 HCAPLUS
CN      D- $\alpha$ -Glutamine, N2-[N-[N-acetyl-1-S-[11-[(3-carboxy-1-
        oxopropyl)amino]-1-oxoundecyl]-6-O-(1-oxodecyl)-1-thio- $\beta$ -muramoyl]-L-
        alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[[1-oxo-3-[(1-
        oxotetradecyl)oxy]tetradecyl]amino]- $\beta$ -D-glucopyranose 4-(dihydrogen
        phosphate) 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)

```





L31 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Selective pivaloylation of 2-(acetamido)-2-deoxy sugars  
 GI



AB Selective pivaloylation of 2-acetamido-2-deoxy-D-glucose, its Me  $\alpha$ - and  $\beta$ -glycosides, and the Me  $\alpha$ -glycoside of N-acetyl-D-muramic acid I was studied under various conditions. The structures of the products were established by  $^1\text{H-NMR}$  spectroscopy and acetylation. The orders of acylation, HO-6 > HO-3 > HO-1 > HO-4 for 2-acetamido-2-deoxy-D-glucose and HO-6 > HO-3 > HO-4 for its Me glycosides, were established. Me 2-acetamido-2-deoxy-3,6-di-O-pivaloyl- $\alpha$ - and  $\beta$ -D-glucopyranosides and 2-acetamido-2-deoxy-1,3,4,6-tetra-O-pivaloyl-D-glucopyranose were hydrolyzed by rabbit serum esterases.

AN 1989:213238 HCAPLUS <<LOGINID::20080616>>

DN 110:213238

OREF 110:35402h,35403a

TI Selective pivaloylation of 2-(acetamido)-2-deoxy sugars

AU Ljevakovic, Durdica; Tomic, Srdanka; Tomasic, Jelka

CS Dep. Radioimmunol., Inst. Immunol., Zagreb, 41000, Yugoslavia

SO Carbohydrate Research (1988), 182(2), 197-205

CODEN: CRBRAT; ISSN: 0008-6215


DT Journal

LA English

OS CASREACT 110:213238


IT 19229-53-9  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (pivaloylation of)  
 RN 19229-53-9 HCAPLUS  
 CN  $\alpha$ -Isomuramic acid, N-acetyl-1-O-methyl-, methyl ester (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




IT 120489-44-3P 120489-47-6P 120489-56-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and acetylation of)  
 RN 120489-44-3 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranose, 2-(acetylamino)-2-deoxy-, 1,3,6-tris(2,2-  
 dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.



RN 120489-47-6 HCAPLUS  
 CN  $\alpha$ -Muramic acid, N-acetyl-1-O-methyl-, methyl ester,  
 6-(2,2-dimethylpropanoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 120489-56-7 HCAPLUS

CN  $\beta$ -D-Glucopyranose, 2-(acetylamino)-2-deoxy-, 1,3,6-tris(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




IT 120489-33-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation, acetylation and enzymic hydrolysis of)

RN 120489-33-0 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-,  
3,6-bis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




IT 120489-51-2P

RL: SPN (Synthetic preparation); PREP (Preparation)



(preparation, acetylation, pivaloylation and enzymic hydrolysis of)  
 RN 120489-51-2 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-,  
 3,6-bis(2,2-dimethylpropanoate) (CA INDEX NAME)


Absolute stereochemistry.



L31 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Disaccharide  
 GI For diagram(s), see printed CA Issue.  
 AB Disaccharides I (R = alkyl, hydroxyalkyl or protected hydroxy alkyl of 7-19 C atoms; R1 = allyl, benzyl, 1-propenyl, trichloroethyl; R2 = H, RCO; R3 = allyl, crotyl, MeOCH2CH2OCH2, MeSCH2, benzyl; R4 = H, ClCH2CO,  $\beta$ -benzoylpropionyl), useful in the preparation of lipid A analogs, were prepared via coupling of the component monosaccharides by oxazoline method. Thus, I [RCO = palmitoyl, R1 = R3 = benzyl, R2 = palmitoyl, R4 = (Cl3CCH2O)2P(O)] was prepared in several steps starting from allyl and benzyl 3,4,6-tri-O-acetyl-2-deoxy-2-palmitamido- $\beta$ -D-glucopyranoside.  
 AN 1985:422874 HCAPLUS <<LOGINID::20080616>>  
 DN 103:22874  
 OREF 103:3791a,3794a  
 TI Disaccharide  
 IN Anderson, Laurens; Nashed, Mina A.  
 PA Wisconsin Alumni Research Foundation, USA  
 SO U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 248,692, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4495346	A	19850122	US 1982-433055	19821006 <--
PRAI	US 1981-248692	A2	19810330	<--	
OS	MARPAT 103:22874				
IT	78835-44-6P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation and chloroacetylation of)				
RN	78835-44-6 HCAPLUS				
CN	$\beta$ -D-Glucopyranoside, 1-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)-, 6-hexadecanoate (9CI) (CA INDEX NAME)				

Absolute stereochemistry.  
 Double bond geometry unknown.




IT 78835-47-9P 78835-48-0P 84766-03-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and glycosylation of, with (glucopyrano)oxazoline derivative)  
 RN 78835-47-9 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-,  
 3-hexadecanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 78835-48-0 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, phenylmethyl 2-deoxy-2-[(1-oxohexadecyl)amino]-,  
 3-hexadecanoate (CA INDEX NAME)

Absolute stereochemistry.




RN 84766-03-0 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 1-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-,  
 3-hexadecanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




IT 78835-43-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and isomerization of)  
RN 78835-43-5 HCAPLUS  
CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-3-O-  
(phenylmethyl)-, 6-hexadecanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 84766-03-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and reaction of, with (glucopyrano)oxazoline derivative)  
RN 84766-03-0 HCAPLUS  
CN  $\beta$ -D-Glucopyranoside, 1-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-,  
3-hexadecanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




IT 78835-42-4P 78835-49-1P 78853-09-5P  
 84766-02-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and reaction of, with palmitoyl chloride)  
 RN 78835-42-4 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-3-O-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 78835-49-1 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 2-propenyl 6-O-[4-O-(chloroacetyl)-2-deoxy-6-O-  
 (1-oxohexadecyl)-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)- $\beta$ -D-  
 glucopyranosyl]-2-deoxy-2-[(1-oxohexadecyl)amino]-, 3-hexadecanoate (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 78853-09-5 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, phenylmethyl 6-O-[4-O-(chloroacetyl)-2-deoxy-6-O-(1-oxohexadecyl)-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-2-deoxy-2-[(1-oxohexadecyl)amino]-, 3-hexadecanoate (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 84766-02-9 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 1-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.



IT 78835-52-6P 78853-10-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 78835-52-6 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-6-O-(1-oxohexadecyl)-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-2-[(1-oxohexadecyl)amino]-, 3,4-dihexadecanoate (CA INDEX NAME)


Absolute stereochemistry.



RN 78853-10-8 HCAPLUS

CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-6-O-[2-deoxy-6-O-(1-oxohexadecyl)-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-2-[(1-oxohexadecyl)amino]-, 3,4-dihexadecanoate (9CI) (CA INDEX NAME)




Absolute stereochemistry.



L31 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis of liposaccharide corresponding to fundamental structure of Salmonella-type lipid A

GI



AB The glucopyranose I, which is the fundamental structure of lipid A without the phosphate moiety, was prepared by stepwise introduction of the acyl groups into the disaccharide II. Thus, II prepared by sequential coupling of monosaccharides III ( $R = \text{Ac}$ ,  $R_1 = \text{CH}_2\text{Ph}$ ,  $R_2 = \text{H}$ ,  $R_3 = \text{Cl}$ ;  $R = R_3 = \text{H}$ ,  $R_1 = \text{Bz}$ ,  $R_2 = \text{OCH}_2\text{CH}:\text{CH}_2$ ), acetylation, and N-deacetylation, was treated with  $\text{Me}(\text{CH}_2)_{12}\text{COCl}$  to give an N,N-dimyristoyl disaccharide, which was saponified to remove the O-acyl groups. Reaction of the product with  $\text{Me}_2\text{C}(\text{OMe})_2$  gave semiprotected product IV. The OH groups of IV were acylated with  $\text{Me}(\text{CH}_2)_{12}\text{COCl}$  and the product hydrolyzed, and selectively reacylated, followed by hydrogenolytic cleavage of the  $\text{CH}_2\text{Ph}$  group to give 97% I.

AN 1981:175390 HCAPLUS <<LOGINID::20080616>>

DN 94:175390

OREF 94:28675a,28678a

TI Synthesis of liposaccharide corresponding to fundamental structure of Salmonella-type lipid A

AU Inage, Masaru; Chaki, Haruyuki; Kusumoto, Shoichi; Shiba, Tetsuo

CS Dep. Chem., Osaka Univ., Osaka, 560, Japan

SO Tetrahedron Letters (1980), 21(40), 3889-92

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English


IT 76994-69-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and acylation of)

RN 76994-69-9 HCAPLUS


CN D-Glucose, 2-deoxy-6-O-[2-deoxy-2-[(1-oxotetradecyl)amino]-3-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-2-[(1-oxotetradecyl)amino]-, 3,4-ditetradecanoate (CA INDEX NAME)

Absolute stereochemistry.



IT 76994-62-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and coupling reaction of, with monosaccharide)  
 RN 76994-62-2 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-, 3-benzoate  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 76994-66-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and cyclocondensation reaction of, with dimethoxypropane)  
 RN 76994-66-6 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-deoxy-6-O-[2-deoxy-2-[(1-oxotetradecyl)amino]-3-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-2-[(1-oxotetradecyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






IT 76994-70-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and hydrogenolysis of)  
 RN 76994-70-2 HCAPLUS  
 CN D-Glucose, 2-deoxy-6-O-[2-deoxy-6-O-(1-oxotetradecyl)-2-[(1-oxotetradecyl)amino]-3-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-2-[(1-oxotetradecyl)amino]-, 3,4-ditetradecanoate (CA INDEX NAME)

Absolute stereochemistry.




IT 76994-63-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation, acetylation, and N-deacetylation of)  
 RN 76994-63-3 HCAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-6-O-[4,6-di-O-acetyl-2-(acetylamino)-2-deoxy-3-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]-, 3-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L31 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN  
 TI Introduction of a benzyl protecting group in place of acetyl in partially  
 acetylated sugars  
 GI



AB Benzylation of partially acetylated amino sugar I (R = Ac, R1 = H) by  
 PhCH2Br gave 70% I (R = PhCH2, R1 = H). Analogous benzylation of II (R =  
 Ac, R1 = H) gave 63% II (R = PhCH2, R1 = H).  
 AN 1980:215727 HCAPLUS <<LOGINID::20080616>>  
 DN 92:215727  
 OREF 92:34967a,34970a  
 TI Introduction of a benzyl protecting group in place of acetyl in partially  
 acetylated sugars  
 AU Bovin, N. V.; Zurabyan, S. E.; Khorlin, A. Ya.  
 CS Inst. Bioorg. Khim., Moscow, USSR  
 SO Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1980), (1),  
 215-17  
 CODEN: IASKA6; ISSN: 0002-3353  
 DT Journal  
 LA Russian  
 IT 67535-70-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (benzylation of, by benzyl bromide)  
 RN 67535-70-0 HCAPLUS  
 CN  $\alpha$ -D-Glucopyranoside, phenylmethyl 2-(acetylamino)-2-deoxy-,  
 4,6-diacetate (CA INDEX NAME)

Absolute stereochemistry.



IT 73646-11-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 73646-11-4 HCAPLUS

CN α-D-Glucopyranoside, phenylmethyl 2-(acetylamino)-2-deoxy-4,6-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.

